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Abstract 
 
 Multiple independent transfers of simian immunodeficiency virus (SIV) strains 
from chimpanzees to human populations produced the current HIV-1 pandemic. We 
hypothesized that Central African human populations may have been exposed to SIV 
prior to the current pandemic, and that previous local outbreaks may have selected for 
genetic resistance to immunodeficiency viruses. To test this hypothesis, I examined the 
genomes of Biaka Western pygmies, who historically have resided in forests within the 
range of the only chimpanzee subspecies (Pan troglodytes troglodytes) that carries strains 
of SIV ancestral to HIV-1. SNP genotypes of the Biaka were compared to those of an 
Eastern pygmy population and to other African groups residing outside the range of P. t. 
troglodytes. Genomic regions showing signatures of selection were compared to the 
genomic locations of AIDS restriction genes (ARGs), genes with known variants that 
affect HIV-1 infection or AIDS progression. In the Biaka, a strong signal of selection was 
detected at the ARG CUL5, with a modest signal of selection at the ARG TRIM5. Using a 
different test of selection, Biaka genomes showed a strong signal of selection at the ARG 
TSG101. Pygmies have also been found to carry genotypes protective against HIV-1 for 
the ARGs CCR2, CCL3L1 and CCR5. 
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Chapter 1. Review of Literature
1
 
History of the HIV pandemic 
 The first indication of the modern HIV/AIDS epidemic was a 1981 outbreak of 
Pneumocystis pneumonia in Los Angeles. Pneumocystis carinii pneumonia, an 
opportunistic parasitic infection, was detected in five previously healthy young 
homosexual men (Gottlieb 2006). Other reports of opportunistic infections present in 
otherwise healthy young individuals characterized the later named Acquired 
Immunodeficiency Syndrome (AIDS). Patients were often diagnosed with candidiasis, 
also known as thrush, a fungal infection seen only in highly immune compromised 
individuals (Zaidi et al. 2002). Patients diagnosed with AIDS had a higher incidence of 
certain cancers, caused by co-infection with other, oncogenic viruses (Boshoff et al. 
2002; Yarchoan et al. 2005). Among these cancers, Kaposi's sarcoma, certain B-cell non-
Hodgkin's lymphomas, and invasive cervical cancer were all considered to be AIDS-
defining conditions (Yarchoan et al. 2005). HIV-1, the virus that causes the immune 
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 Figure 1.1 is reprinted from a publication by the Joint United Nations Programme on HIV/AIDS. Joint 
United Nations Programme on HIV/AIDS [UNAIDS] (2010). Global report: UNAIDS report on the global 
AIDS epidemic 2010. 
Figure 1.2 is reprinted from a publication by Freed et al. 2003. Freed, E. (2003). HIV-1 Replication. 
Lentiviral Vector Systems for Gene Transfer. G. L. Buchschacher. 
Figure 1.3 is reprinted from a publication by Turner et al. 1999. Turner, B. G. and M. F. Summers (1999). 
"Structural biology of HIV." Journal of Molecular Biology 285(1): 1-32. 
Figure 1.4 is reprinted from a publication by McCutchan et al. 2006. McCutchan, F. E. (2006). "Global 
epidemiology of HIV." Journal of Medical Virology 78(S1): S7-S12. 
Figures 1.5 and 1.6 are reprinted from a publication by Sharp et al. 2010. Sharp, P. M. and B. H. Hahn 
(2010). "The evolution of HIV-1 and the origin of AIDS." Philos Trans R Soc Lond B Biol Sci 365: 2487-
2494. 
Figure 1.7 is reprinted from a publication by Cavalli-Sforza et al. 2005.  Cavalli-Sforza, L. L. (2005). "The 
Human Genome Diversity Project: past, present and future." Nat Rev Genet 6: 333-340. 
All figures reprinted within fair use guidelines. 
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system dysfunction resulting in AIDS was first isolated in 1983 (Barre-Sinoussi et al. 
1983).  
  Clinical trials for the first HIV-1 treatment, the drug zidovudine, began in 1987. 
(Ezzell 1987). The drug acts as a nucleoside analog that blocks the function of the viral 
reverse transcriptase enzyme and thus prevents viral integration into new host cells 
(Pomerantz et al. 2003). However, development of these nucleoside inhibitors was unable 
to stop the spread of HIV-1 and by 1993, AIDS had become the number one killer of 
young adults in the United States (Pomerantz et al. 2003). Protease inhibitors were 
developed by 1995, providing a second mechanism for delaying AIDS (Dorsey et al. 
1994). These inhibitors blocked cleavage of newly synthesized HIV-1 peptides, 
preventing them from being modified into mature, functional enzymes (Richman 2001). 
The combination of nucleoside analogs and protease inhibitors provided the basis for 
highly active antiviral therapy (HAART), a treatment that would delay the onset of AIDS 
by more than four years (Gulick et al. 2000). Subsequently, an increased understanding of 
the mechanisms involved in reverse transcriptase and viral membrane fusion provided 
additional drug targets (Pomerantz et al. 2003). 
 By 2009, cumulatively over one million individuals in the United States had been 
diagnosed with AIDS and approximately 500,000 deaths had resulted from the disease 
(Centers for Disease Control 2009). Worldwide, currently 33 million people are 
estimated to be infected with HIV-1 (Figure 1.1) and only approximately 5 million are 
receiving treatment (Joint United Nations Programme on HIV/AIDS [UNAIDS] 2010). 
The incidence of HIV-1 is particularly high in sub-Saharan Africa, where the adult 
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prevalence of HIV-1 may be as high as 25.9% in some countries (Figure 1.1). Sub-
Saharan Africa has a total of 22.5 million individuals infected with HIV-1 (Joint United 
Nations Programme on HIV/AIDS [UNAIDS] 2010)  
 HIV-1 and other retroviruses comprise a family of enveloped RNA viruses, 
characterized by their ability to integrate themselves into the host cellular nuclear genome 
and their dependence on reverse transcription of their viral RNA genome into DNA upon 
entry into a host cell (Coffin et al. 1997). Retroviruses have high replicative potential and 
low replicative fidelity, generating mutations that can exploit vulnerabilities in the host 
cell's defense. After reverse transcription, the DNA is imported into the nucleus where a 
viral enzyme, integrase, splices it into the host cell genome, allowing it to be transcribed 
using the same cellular mechanisms as other genes. 
 Retroviruses are enveloped by an outer lipid membrane, coated with surface 
glycoproteins and with transmembrane proteins (Figure 1.2) (Coffin et al. 1997). Inside 
this outer lipid membrane is the retroviral capsid, a protein shell that contains the 
retroviral genome and enzymes such as reverse transcriptase (Figure 1.2). Retroviral 
genomes consist of a pair of linear 7-12 kilobase single-stranded positive-sense RNA 
molecules with genes encoding for soluble proteins (Figure 1.2). All retroviruses, 
including HIV-1, have four major protein coding regions: the group-specific antigen 
(gag), which provides the structural proteins of the viral capsid, the polymerase (pol) 
region that codes for the viral reverse transcriptase and integrase enzymes, and the 
envelope (env) region which encodes the surface and transmembrane proteins on the viral 
envelope. Additionally, all retroviruses have a smaller coding domain for protease (pro). 
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Complex retroviruses, including HIV-1, also encode for additional host-regulatory 
proteins, derived from alternative splicing of the viral RNA (Turner et al. 1999). 
HIV-1 uses its surface and transmembrane proteins for host cell recognition and 
binding (Figure 1.3) (Pomerantz et al. 2003). HIV-1 binds to cells expressing the CD4 
glycoprotein marker, then the virus triggers membrane fusion using one of several host 
cell receptors, notably CCR5 and CXCR4 (Figure 1.3) (Turner et al. 1999). The fused 
virus is uncoated and the viral reverse transcriptase enzyme catalyzes conversion of the 
viral genome to DNA, which is subsequently transported to the host cell nucleus (Figure 
1.3) (Turner et al. 1999). Viral enzymes facilitate transport and insertion of the nascent 
DNA molecule to into the host genome. Replicates of the virus are produced by 
transcription, translation, and post-translational modification of the inserted provirus by 
host cell enzymes (Figure 1.3) (Pomerantz et al. 2003).  
As noted above, an impaired host immune system is a hallmark of late-stage HIV-
1 infection. A commonly-used indicator of progression from HIV-1 infection to AIDS is 
the concentration of T lymphocytes bearing CD4 receptor on the cell membrane 
(Grossman et al. 2002; Giacca 2005). The mechanisms of HIV-1 driven CD4 cell 
depletion are still not fully understood, but the HIV-1 transactivator protein (Tat) and 
gp120 surface glycoprotein have been shown to promote CD4 cell apoptosis in vivo 
(Cummins et al. 2010). 
Diversity and origin of HIV-1  
HIV-1 occurs in humans as four phylogenetically divergent groups (Figure 1.4). 
Group M ("major") is the most common accounting for more than 95% of the global 
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pandemic. Group M has been further subdivided into at least nine subtypes: A, B, C, D, 
F, G, H, J, and K (Figure 1.4) (McCutchan 2006). Multiple subtypes that infect a single 
individual can recombine to produce circulating recombinant forms (CRFs). The second 
most common group is O ("outlier"), which is mostly confined to west-central Africa. 
Groups N and P have only been found in a few individuals in Cameroon (Figure 1.4) 
(Plantier et al. 2009; Sharp et al. 2010). The presence of very distinctive forms of HIV-1 
in Cameroon points to Central Africa as the origin of HIV-1 (Sharp et al. 2010). 
Sequence analysis of simian immunodeficiency viruses (SIV) have identified 
them as the progenitors of HIV-1. The closest SIV strains to HIV-1 have been detected in 
the common chimpanzee, Pan troglodytes (Figure 1.5) (Keele et al. 2006). A phylogeny 
of chimpanzee SIV strains and human HIV-1 groups revealed that HIV-1 sequences are 
polyphyletic in humans: each of the four HIV-1 groups present in humans is closer in 
sequence to strains of SIV present in the central African subspecies (P.t. troglodytes) of 
the common chimpanzee than to HIV-1 sequences belonging to other human HIV-1 
groups (Figure 1.6). This suggests that HIV-1 originated in four or more independent 
zoonotic transmissions from the central African common chimpanzee to humans (Figure 
1.6) (Sharp et al. 2010). The natural range of the central African chimpanzee comprises 
the Congolian forest block of Central Africa, west of the Congo River (Figure 1.5) (Sharp 
et al. 2010), suggesting that the various HIV-1 groups may have first infected humans 
living in this region, before giving rise to the world-wide pandemic (Figure 1.5) (Sharp et 
al. 2010).  
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 Archival medical samples collected in Leopoldville (now Kinshasa, Democratic 
Republic of the Congo) during 1959 and 1960 are the earliest documented evidence of 
HIV-1 infections in humans. The diversity of HIV-1 present in these and in subsequently 
collected samples allowed the date of cross-species transmission for HIV-1 clade M 
viruses to be estimated as having occurred between 1884 and 1924 (Worobey et al. 
2008). Thus, it seems likely that HIV-1 has been present in humans for not more than a 
century or two (Worobey et al. 2008). 
Hypothesis 
 Since SIV has likely been present in chimpanzees for at least 32,000 years 
(Worobey et al. 2010) and since HIV-1 has crossed the species barrier from chimpanzees 
to humans multiple times within little more than a century, we considered whether a virus 
known to repeatedly cross the species barrier from chimpanzees to humans would only 
begin to do so in the past century. We hypothesized that the virus may have crossed the 
species barrier into local human populations before the current pandemic, with outbreaks 
prior to the current pandemic extinguished due to local disappearance of infected groups, 
or quick susceptibility of immunodeficient individuals to formerly pervasive infectious 
diseases (e.g., smallpox). If immunodeficiency viruses had crossed the species barrier 
before the current pandemic, this may have led to selection for resistance among local 
human populations, which could be reflected as genomic signatures in their living 
descendants. 
 To examine this hypothesis, we sought to find a human population for which 
abundant genomic data was available that has historically resided in the range of the SIV 
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strain that was the progenitor to HIV-1. We found that the Biaka are the only human 
group residing in this region that were also part of the Human Genome Diversity Project 
(HGDP), a collection of human samples from 52 world populations for which a large 
amount of genomic data has been generated (Figure 1.7) (Cavalli-Sforza 2005). The 
Biaka pygmies are a human population who have resided in communities in the tropical 
forests of what is now the Central African Republic for tens of thousands of years 
(Cavalli-Sforza 1986; Verdu et al. 2009), and may have been exposed to chimpanzee 
pathogens through bushmeat or from keeping them as pets (Cavalli-Sforza 1986; Bailey 
1991). Their communities have resided in the region where the strains of SIV that gave 
rise to HIV-1 are endemic. This study sought to find evidence for selection at host genes 
that interact with HIV-1 using the Biaka genomic dataset. 
Host genes that interact with HIV-1 
 Host genes that have variants known to affect HIV-1 infection or AIDS 
progression are called AIDS restriction genes (ARGs) (Table 1.1). Most of the human 
host genetic factors known to affect HIV infection have been uncovered by genotyping 
cohorts of patients or high risk groups established in the 1980s. Cohorts that have been 
established of intravenous drug users, persons with hemophilia, and men who have sex 
with men (An et al. 2010). As an example, the AIDS link to intravenous experience 
(ALIVE) study, examined a cohort of intravenous drug users in Baltimore, Maryland. 
The study tracked groups of injection drug users over time (longitudinal study design), 
who may or may not have been infected with HIV-1 at the time of enrollment but did not 
meet the criteria for AIDS. Some 2958 patients were semiannually interviewed and 
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screened for HIV-1 infection and AIDS seroconversion status (Dean et al. 1996; Smith 
1997). The medical information collected for this cohort was later used to determine 
whether the individual genotypes of the participants may have been detrimental or 
beneficial in terms of HIV-1 infection or pathology. 
 ARGs were uncovered from patients in ALIVE and other cohorts who 
demonstrated extreme phenotypes with regards to HIV susceptibility or AIDS 
progression (O'Brien et al. 2004). The first ARG discovered was a variant of the C-C 
chemokine receptor type 5 (CCR5) gene with a 32-base pair exonic deletion that results 
in a truncated peptide in this cellular receptor. The polymorphism affords near complete 
protection against HIV-1 in homozygotes and delays AIDS progression in heterozygotes . 
Chemokine receptors comprise a class of receptors for cell signaling proteins 
predominantly found in white blood cells (Murdoch et al. 2000). The genes CCR2 and 
CXCR6 were also found to have known variants that affected AIDS progression. CCR2 
has a non-synonymous valine to isoleucine mutation that delays AIDS progression 
(Smith et al. 1997; Smith 1997). Even though CCR2 is adjacent to CCR5 and is in high 
linkage disequilibrium with CCR5, a report controlling for associations with CCR5-
delta32 found a variant that delays AIDS progression (Smith 1997; Mariani et al. 1999). 
CXCR6 is a chemokine receptor and the primary coreceptor for SIV infection in non-
human primates, and is also believed to be involved in late-stage HIV-1 infection in 
humans.  
 A total of 45 ARGs at 26 loci have been discovered, that may be broadly placed 
into 4 gene categories—cell receptors and ligands required for HIV-1 entry, viral 
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restriction factors, cytokines and human leukocyte antigen (HLA) genes (Table 1.1). The 
first category of ARGs, variants in cell receptors, such as CCR5, described above, have 
been shown to affect HIV-1 infection and AIDS progression, by eliminating a route for 
HIV-1 cell entry (Smith 1997; Pomerantz et al. 2003). Also in this first category of ARGs 
are variants in the ligand corresponding to cell receptors, which can compete with HIV-1 
for receptor binding sites (Pomerantz et al. 2003). An example is the gene RANTES, 
which encodes a small signaling peptide that binds to CCR5. A variant in RANTES 
increases the number of ligands produced that compete with HIV-1 binding to cellular 
receptors necessary for HIV-1 infection (Zagury et al. 1998; Liu et al. 1999).  
 The second category of ARGS are viral restriction factors, which are host 
enzymes in the immune system that restrict viral infection. Alleles in viral restriction 
factors, such as the APOBEC3 gene family responsible for degrading retroviruses, have 
been shown to significantly alter the rate AIDS progression in patients (O'Brien et al. 
2004).  The third category of ARGS are cytokines, which are small protein molecules 
responsible for cell signaling. An example is a polymorphic allele in the promoter of the 
IL10 gene, which increases transcription of the gene and ultimately signals for fewer cells 
to be available for HIV-1 infection (Shin et al. 2000). The fourth category of ARGs are 
polymorphisms in the human leukocyte antigen (HLA) loci, which are involved in 
recognition of antigens for acquired immunity. Polymorphisms in the HLA class I loci 
and the killer cell immunoglobulin-like receptor (KIR) genes, which code for proteins 
that interact with HLA class I, have also been shown to affect rates of HIV-1 infection 
(Carrington et al. 2008). 
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 In addition to ARGs, I also considered host genes that have a role in the lifecycle 
of HIV-1, but do not have variants known to affect HIV-1 infection or AIDS progression. 
These genes, referred to as HIV dependency factors (HDFs), were found by three studies. 
These studies used small-interfering RNAs (siRNAs) to test for genes that were not 
crucial for cell viability but played a role in HIV-1 infection or replication (Brass et al. 
2008; Konig et al. 2008; Zhou et al. 2008). In each study, one "pool" of siRNAs 
corresponding to a gene was introduced to a CD4 cell or CD4-like cell along with HIV or 
a HIV analog (Brass et al. 2008; Konig et al. 2008; Zhou et al. 2008). Each pool of 
siRNAs would "knock down", or interfere with the transcription of its target gene. Genes 
for which the knockdown did not result in cell death, but which significantly decreased 
HIV-1 infection or replication were assumed to normally facilitate infection, and were 
thus deemed HIV dependency factors (HDFs) (Goff 2008). In the first of the three 
studies, Brass et al. used cultured human HeLa cells with CD4 expression and measured 
beta-galactosidase reporter for tat, the major viral transactivator protein. Of the 21,000 
genes tested, 273 genes were identified whose depletion inhibited HIV-1 p24 production 
or beta-galactosidase activation by more than 2 standard deviations from the mean level 
in controls (Brass et al. 2008). An independent subsequent study by Konig used SV40 T 
antigen- and adenovirus E1A-transformed cultured human 293T cells (Konig et al. 2008). 
Susceptibility to infection was tested using a luciferase reporter gene delivered to cells 
using a replication-infection pseudotyped HIV-1 virus that coded for VSV-G envelope 
proteins. Thus, the Konig et al. (2008) study only screened for genes involved in the early 
stages of infection, and would not detect genes involved in HIV-1 envelope-mediated 
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entry. Of 20,000 genes screened by Konig et al. (2008), 295 were found to decrease HIV-
1 infectivity by at least 45% while not significantly decreasing host cell viability (Konig 
et al. 2008). The third screen, by Zhou et al. used HeLa cells expressing CD4 and 
harboring a beta-galactosidase reporter gene responsive to HIV-1 transcription. Unlike 
Brass et al. (2008) , Zhou et al. (2008) infected the cells with the HXB2 strain of HIV-1 
and examined beta-galactosidase activity in the cell 48 hours post-infection to detect the 
first round of viral entry and tat transactivator expression, and 96 hours post-infection to 
detect additional rounds of virus spreading into neighboring cells (Zhou et al. 2008).  
 Although the three siRNA screens had similar goals, the studies showed very little 
overlap in genes identified as host dependency factors. I compared the list of HDFs 
published by each study using the UCSC known gene database to produce a list of 
unique, unambiguous gene names (Fujita et al. 2010). HDFs found by two or three of the 
studies are listed in Table 1.2. Only three genes were identified as HDFs by each of the 
three studies (Table 1.2) (Konig et al. 2008). The different host cells, infection time 
stages, and viral challenges used may be responsible for the lack of overlap in host 
dependency genes detected by the three studies (Goff 2008). 
 For the current study, we hypothesized that since the Biaka lived in a region 
where SIV strains that gave rise to HIV were carried by local non-human primates, the 
ancestors of the Biaka may have been exposed to immunodeficiency viruses, which may 
have selected for protective variants at AIDS restriction genes and HIV dependency 
factors. I wanted to test this hypothesis by looking in the Biaka for signatures of selection 
in genes with variants known to affect HIV-1 infection and AIDS progression (ARGs) 
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and in genes that are required for HIV-1 infection (HDFs). In order to do this I compiled 
a comprehensive list of genes identified as ARGs (Table 1.1) and as HDFs. However, in 
order to test our hypothesis, I would need to find a means of examining the genomes of 
the Biaka pygmies for genomic signatures of selection, and then find the overlap between 
these regions of the genome and the genomic locations of ARGs or HDFs. 
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Figures and Tables 
 
Figure 1.1. Prevalence of the world-wide HIV-1/AIDS pandemic. The UN estimates 
that 33.3 million people were living with HIV at the end of 2009. A disproportionate 
share of the disease burden is carried by sub-Saharan Africa, where 22.5 million people 
are estimated to be living with HIV. The countries with the highest prevalence are in 
southern Africa and include Botswana, Namibia, South Africa, Zambia, and Zimbabwe. 
Figure from: (Joint United Nations Programme on HIV/AIDS [UNAIDS] 2010). 
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Figure 1.2. Structure of HIV-1. HIV-1 is enveloped by a lipid membrane layer, derived 
from the membrane of the human host cell (Turner et al. 1999). Surface and 
transmembrane proteins exposed outside the lipid membrane layer are used for host cell 
recognition and binding, and are derived from host cell proteins (Turner et al. 1999). The 
structural matrix of the virus is required for virion assembly and recent studies have 
shown that it also mediates nuclear import of viral cDNA and possesses multiple 
targeting signals (Hearps et al. 2007). The protein-based, cone-shaped viral capsid 
contains the replication machinery and genome for the virus (Turner et al. 1999). The 
viral capsid also binds and helps package host cyclophilin A, a protein essential for viral 
infectivity (Turner et al. 1999). Inside the capsid are the retroviral enzymes reverse 
transcriptase, protease, integrase, and nucleocapsid, along with the viral RNA genome. 
The nucleocapsid protein chaperones the viral RNA genome and reverse transcriptase 
through the DNA synthesis process (Darlix et al. 2011). Reverse transcriptase catalyzes 
the synthesis of viral cDNA from RNA. Many anti-HIV drugs have targeted reverse 
transcriptase, either by exploiting its differential specificity to nucleosides by providing 
chain-terminating analogs or by binding competitively to the enzyme to inhibit catalysis 
(Turner et al. 1999). Integrase assists in preparing the viral cDNA for integration and 
catalyzing its insertion into the human genome (Coffin et al. 1997). Protease provides 
post-processing functions to the newly synthesized viral peptides (Coffin et al. 1997). Not 
shown are viral proteins Tat, Rev, Vpr, Nef, Vif, and Vpu, which are shown in Figure 
1.2. Figure from: (Freed 2003). 
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Figure 1.3. The HIV-1 life cycle. The HIV-1 glycoprotein gp120, expressed on the 
membrane surface of the virus, is responsible for binding specifically to host cells bearing 
CD4 receptor. Upon binding and fusing to the membrane of the host cell, the retroviral 
machinery is uncoated, and the viral reverse transcriptase (RT) enzyme catalyzes 
synthesis of DNA from the viral RNA template. Newly synthesized viral DNA is 
transported to the nucleus of the host cell with the rest of the pre-integration complex 
including integrase (IN), viral matrix protein (MA), viral reverse transcriptase (RT), and 
viral protein R (Vpr). Vpr aids in localizing the complex to the nucleus and arresting 
growth of infected cells in G2 phase (Turner et al. 1999). Integrase splices the viral DNA 
into the host genome. The late phase of the viral life cycle begins after integration. Short 
spliced RNA transcripts for Tat, Rev, and Nef are synthesized in the nucleus and 
translated by the cellular ribosome. Unspliced or partially spliced HIV mRNA transcripts 
for Gag and Gag-Pol are exported from the nucleus with the aid of the viral Rev 
accessory protein and the transcripts are translated using the cellular ribosomes as well. 
The env transcripts are spliced within the nucleus, synthesized in the endoplasmic 
reticulum, and post-translationally modified, a process continued in the Golgi apparatus, 
until the final trimeric glycoprotein is formed. The trimeric Env protein is transported to 
the cell membrane to initiate virus budding. Other monomeric Env transcripts in the 
endoplasmic reticulum bind to cellular CD4 protein, which are also transcribed in the 
endoplasmic reticulum. The MA domain of the Gag viral protein binds to the inner layer 
of the cellular protein to form the budding virion, carrying along Gag-Pol precursor 
proteins. After budding, the precursor proteins are cleaved by PR to form individual 
proteins. Finally, rearrangement of the structural proteins result in a mature, infectious 
virion. Figure from: (Turner et al. 1999). 
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Figure 1.3 (cont.) 
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Figure 1.4. Worldwide distribution of HIV-1 clades and recombinants in 2004. HIV-
1 occurs in humans as four phylogenetically divergent groups. Group M (major) is the 
most prevalent accounting for more than 95% of the global pandemic, followed by group 
(O) which is mostly confined to west-central Africa. Groups N and P have only been 
found in a few individuals in Cameroon (Plantier et al. 2009; Sharp et al. 2010). West-
central Africa is burdened with the greatest diversity of HIV-1 clades, suggesting that the 
region is the original source of the virus. Note that there is a different HIV virus, 
designated HIV-2, which is non-pandemic, largely restricted to west Africa, and appears 
to have originated in SIV strains of the sooty mangabey (Cercocebus atys atys) (Santiago 
et al. 2005). Figure from: (McCutchan 2006). 
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Figure 1.5. Map showing the ranges of subspecies of the common chimpanzee (Pan 
troglodytes) in west and central Africa. The simian immunodeficiency virus (SIV) 
strains carried by the central chimpanzee subspecies, P. t. troglodytes, are the progenitors 
of HIV-1. The range of the central chimpanzee subspecies includes southern Cameroon, 
Equatorial Guinea, Gabon, Congo, the western portion of the Democratic Republic of the 
Congo, and the south-western region of the Central African Republic. SIV strains closely 
related to HIV-1 group M are found in chimpanzees in the circled region in south-eastern 
Cameroon (Sharp et al. 2010). The western chimpanzee subspecies P. t. verus, whose 
range extends from Senegal in the northwest to western Ghana in the east, are not 
infected with SIV. Similarly, the Nigerian chimpanzee subspecies P. t. ellioti is also not 
infected with SIV. The eastern chimpanzee subspecies P. t. schweinfurthii, has a range 
that extends from the eastern region of the Central African Republic to the eastern 
Democratic Republic of the Congo with a southern boundary at the Congo River. This 
subspecies harbors strains of SIV that are not similar to any HIV-1 strains. The HIV-1 
group O strains are related to the SIV strain carried by the gorilla subspecies, G. g. 
gorilla, whose range overlaps with the range of P. t. troglodytes. It is unclear whether this 
strain was transmitted to humans directly from the gorilla or was transmitted to the 
chimpanzee and then into humans. Figure from: (Sharp et al. 2010). 
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Figure 1.6. Phylogeny of SIV and HIV groups M, N, O, P. The phylogenetic 
relationships are shown for strains of chimpanzee SIVcpz (black are strains from P. t. 
troglodytes, grey from P. t. schweinfurthii; also labeled for each clade), SIVgor (blue, 
strains present in gorillas; BQ664, CP2135, CP684) and human HIV-1 (red). The HIV-1 
strains fall into the groups labeled M, N and O (only two representatives of each group 
are shown), and a recently described fourth lineage (RBF168, also referred to as group 
P). The red cross-bars (the three top cross-hairs and the bottom cross-hair) mark four 
branches on which cross-species transmissions to humans occurred; the two blue (the 
fourth and fifth from the top) cross-bars indicate alternative possible branches on which a 
chimpanzee-to-gorilla transmission may have occurred. Adapted by (Sharp et al. 2010) 
from trees shown in (Takehisa et al. 2009) and (Plantier et al. 2009). 
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Figure 1.7. Populations included in the Human Genome Diversity Project. This map 
shows the locations of 52 populations that are represented in the Human Genome 
Diversity Project. The project was started to provide a large-scale systematic study of 
human genomic variation and today has a collection of renewable cell lines from over 
one-thousand individuals in the 52 world-wide populations (Cavalli-Sforza 2005). The 
Biaka pygmy population, whose communities have historically lived in the forests of 
south-western Central African Republic is of particular interest to our study since it is 
within the region where the strains of SIV that gave rise to HIV-1 are endemic.  
Figure from: (Cavalli-Sforza 2005). 
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Table 1.1. Chromosome locations and descriptions of AIDS Restriction Genes (ARGs): Human genes that affect 
susceptibility to and/or response to HIV-1 infection are listed. Genomic locations were obtained from the UCSC Genome 
Browser build hg18 (Fujita et al. 2010). 
 Gene Location Function References 
1 APOBEC3B 22:37708350-
37718729 
A homozygous deletion of the APOBEC3B gene has been 
associated with increased risk of HIV-1 acquisition, 
progression to AIDS, and increased viral set point. 
(An et al. 2009) 
2 APOBEC3G 22:37803081-
37813694 
A codon-changing variant of APOBEC3G increases rate 
of AIDS progression. 
(An et al. 2004; 
Malim 2009) 
3 APOBEC3H 22:37823235-
37830016 
Several SNPs in APOBEC3H have been shown to be 
correlated with increased Vif-resistant anti-HIV activity. 
(Harari et al. 
2009) 
4 CCL2 17:29606408-
29608333 
Haplotypes of the CCL2-CCL7-CCL11 gene cluster have 
been associated with resistance to HIV-1 infection. 
Additionally, a coding variant in CCL2 has been noted to 
delay the onset of AIDS. 
(Smith et al. 
1997; Modi et al. 
2003) CCL7 17:29621352-
29623369 
CCL11 17:29636799-
29639312 
5 CCL3 17:31439715-
31441619 
Haplotypes of the CCL3-CCL4-CCL18 gene cluster have 
been associated with accelerated AIDS progression. 
  
(Modi et al. 2006) 
CCL4 17:31455332-
31457127 
CCL18 17:31415755-
31422954 
6 CCL3L1 17:31546381-
31548269 
17:31647955-
31649843 
Increased copy number of CCL3L1 has been shown to be 
protective against HIV-1 infection and AIDS progression. 
The human genome reference sequence has two copies of 
the gene; individuals have been genotyped with zero to ten 
copies of this gene. 
(Gonzalez et al. 
2005; Kulkarni et 
al. 2008) 
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Table 1.1 (cont.)  
 Gene Location Function References 
7 CCL5 17:31222608-
31231490 
Variants in CCL5 have been shown to increase 
susceptibility to HIV-1, and both increase and decrease 
the rate of AIDS progression. 
(Liu et al. 1999; 
An et al. 2002) 
8 CCR2 3:46370238-
46377429 
The CCR2-64I coding variant has been shown to have a 
protective effect against AIDS progression 
(Smith 1997; 
Mariani et al. 
1999) 
9 CCR5 3:46386636-
46392701 
A 32 base-pair deletion results in a truncated HIV-1 
coreceptor which prevents HIV-1 acquisition and delays 
AIDS. SNPs in CCR5 and its promoter regions have been 
associated with both protection against AIDS and 
increased susceptibility. 
(Dean et al. 1996; 
An et al. 2000) 
10 CUL5 11:107384617-
107483698 
The CUL5 protein is recruited by HIV-1 as part of a 
complex to disable the human APOBEC3G antiviral 
mechanism. SNPs in CUL5 have been associated with 
both accelerated and delayed AIDS progression. 
(An et al. 2007a) 
11 CXCL12 10:44185610-
44200548 
A polymorphism in the CXCL12 3' UTR increases the 
level of CXCL12 mRNA and enhances mRNA stability of 
CXCL12. The protein is protective against AIDS. 
(Winkler et al. 
1998; Garcia-
Moruja et al. 
2009) 
12 CXCR6 3:45959976-
45964849 
A codon-changing variant in CXCR6 accelerates AIDS 
progression. 
(Duggal et al. 
2003; Manfredi et 
al. 2005) 
13 DC-SIGN 
(CD209) 
19:7710881-
7718406 
A SNP in DC-SIGN has been associated with increased 
risk of perinatal transfer of HIV-1.  
(Martin et al. 
2004) 
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Table 1.1 (cont.) 
 Gene Location Function References 
14 HLA-A 6:29963507-
30085130 
Several variants in the HLA region have been shown to 
affect rates of AIDS progression and HIV transmission. 
(Carrington et al. 
1999; Gao et al. 
2001; 
Mackelprang et 
al. 2008; Tang et 
al. 2008b) 
HLA-B 6:31429627-
31432968 
HLA-C 6:31344507-
31347834 
15 IFNG 12:66834816-
66839788 
A SNP in INFG has been associated with accelerated 
AIDS progression. 
(An et al. 2003) 
16 IL10 1: 205007570-
205012659 
A SNP in the 5' promoter region of IL10 has been linked 
to enhanced HIV-1 infection and accelerated AIDS 
progression. 
(Shin et al. 2000) 
17 IL10RA 11:117362318-
117377404 
A SNP in IL10RA was associated changes in the rate of 
AIDS progression. 
(Shrestha et al. 
2010) 
18 IL10RB 22:33542883-
33591390 
Several SNPs in IL10RB have been associated with 
changes in HIV-1 infection and AIDS progression. 
(Shrestha et al. 
2010) 
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Table 1.1 (cont.) 
 Gene Location Function References 
19 KIR2DL1 19:59973076-
59987590 
The KIR locus on chromosome 19 comprises of a family 
of highly homologous genes that are receptors for HLA 
ligands. Interactions between KIR and HLA genotypes 
affect HIV infectivity and AIDS progression. 
 
The human genome reference sequence does not contain 
some KIR genes and thus positions are not available.  
(Carrington et al. 
2008; Martin et 
al. 2008) KIR2DL2 19:59942764-
59987590 
KIR2DL3 19:59927795-
59956316 
KIR2DL4 19:59989604-
60017784 
KIR2DL5  
KIR2DL5B  
KIR2DP1  
KIR2DS2 19:59927795-
60051835 
KIR2DS3  
KIR2DS5  
KIR3DL1 19:59989604-
60034045 
KIR3DL3 19:59927795-
60001550 
KIR3DP1 19:59927795-
60001550 
KIR3DS1  
20 LEDGF 9:15454064-
15501003 
Haplotypes of LEDGF are associated with variation in 
HIV-1 infection and AIDS progression. 
(Madlala et al. 
2011) 
21 PARD3B 2:205118760-
206188782 
SNPs in PARD3B have been associated with variance in 
AIDS progression in a genome-wide association study. 
(Troyer et al. 
2011) 
22 PP1A 11:66922227-
66925651 
Several SNPs found in PP1A have been associated with 
accelerated AIDS progression. 
(An et al. 2007b) 
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Table 1.1 (cont.) 
 Gene Location Function References 
23 PROX1 1:212228482-
212276385 
A haplotype in PROX1 has been associated with delayed 
AIDS progression. 
(Herbeck et al. 
2010) 
24 RPA12 
(ZNRD1) 
6:30137014-
30140665 
A genome-wide association study found significant 
association between ZNRD1 and variation in AIDS 
progression. 
(Fellay et al. 
2007) 
25 TRIM5 11:5641363-
5916425  
Several SNPs in TRIM5 have been associated with 
differential HIV-1 infection rates. Additionally, a null 
allele has been found in Baka pygmies that lacks the 
crucial SPRY domain in the encoded TRIM5-alpha 
protein. 
(Javanbakht et al. 
2006; Torimiro et 
al. 2009) 
26 TSG101 11:18458433-
18505065 
Three haplotypes identified in TSG101 have been 
associated with different rates of AIDS progression. 
(Bashirova et al. 
2006) 
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Table 1.2. List of HDFs detected by two or more gene knock-down studies. HIV-
dependency factors have been identified by three different studies (Brass et al. 2008; 
Konig et al. 2008; Zhou et al. 2008). However, a comparison of the genes identified as 
HDFs found little overlap across the 3 studies. Since a single gene may have been given 
multiple names, I devised a more comprehensive method of comparing lists of HDFs 
reported by different studies. Gene names were matched to unique IDs in the UCSC 
known genes database (Fujita et al. 2010). UCSC unique IDs reported by more than one 
study were converted back to a non-redundant list of gene names, to create the list shown 
here. One previous review (Goff 2008) had reported that 13 genes HDFs had been found 
by both Brass et al. (2008) and Konig et al. (2008) and my program found the same 
number of genes in common. Goff (2008) found 15 HDFs to have been in common in 
both Brass et al. (2008) and Zhou et al. (2008), while my program found 18 HDFs 
reported by both studies, presumably because my program was able to identify genes 
which had been given different names across the studies. Goff did not examine 
similarities between any other study-pair. However, I found that 10 HDFs had been 
reported by both Konig et al. (2008) and Zhou et al. (2008). I also found that only three 
genes were reported by all three studies.  
 
Gene Name Brass  Konig Zhou 
MED6 x x x 
MED7 x x x 
RELA x x x 
CTDP1 x x 
DMXL1 x x 
IDH1 x x 
MAP4 x x 
MED14 x x 
MID1IP1 x x 
NUP153 x x 
RANBP2 x x 
TNPO3 x x 
TRIM55 x x 
ADRBK1 x x 
ANAPC2 x x 
CHST1 x x 
CRSP9 x x 
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Table 1.2 (cont.) 
Gene Name Brass  Konig Zhou 
MED19 x x 
MRE11A x x 
PRDM10 x x 
AKT1 x x 
ANKRD30A x x 
CAV2 x x 
CD4 x x 
CXCR4 x x 
JAK1 x x 
MED28 x x 
MED4 x x 
NUP155 x x 
RAB28 x x 
RGPD8 x x 
RNF26 x x 
TCEB3 x x 
WNK1 x x 
ZNF688 x x 
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Chapter 2. Selection in African Human Populations
2
 
Natural selection 
 Natural selection, as defined by Darwin and elaborated by Fisher, is the 
differential reproduction of genotypes in succeeding generations (Darwin 1859; Jobling 
2004). The aggregate value of the ability of a genotype to survive and reproduce is 
captured in its fitness, which is dependent on the expressed phenotype and its 
environment (Hedrick 2005). Directional selection, or selection that favors one allele, 
drives the disfavored allele toward extinction although the degree of allele frequency 
change is affected by the relative fitness afforded by the allele and by its frequency in the 
population (Hedrick 2005). 
 Mutation introduces new alleles to a population—most new mutations have a 
neutral or nearly neutral effect on fitness although some new mutations are lethal or 
detrimental and a smaller minority are beneficial (Hedrick 2005). Two types of 
directional selection may occur. Purifying selection, or selection against the deleterious 
variants, results in the maintenance of functional genetic features. Darwinian, or positive 
selection operates on the few novel alleles that afford advantageous phenotypes. 
  In overdominant selection, the heterozygote genotype has higher fitness than 
either of the two homozygote genotypes (Hedrick 2005). The population mean fitness is 
at a maximum when the allele frequencies are at a stable equilibrium frequency, which is 
dependent on the relative fitness of the homozygote genotypes. If the relative fitness of 
                                                 
 
2
 Figure 2.2 is reprinted from a publication by Oleksyk et al. 2008 under fair use guidelines. Oleksyk, T. 
K., K. Zhao, et al. (2008). "Identifying selected regions from heterozygosity and divergence using a light-
coverage genomic dataset from two human populations." PLoS One 3: e1712. 
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the homozygotes are equal, the equilibrium allele frequency for each allele would be the 
reciprocal of the number of alleles (Hedrick 2005). This mode of selection is often found 
in immune system genes (Ferrer-Admetlla et al. 2008), where different alleles may be 
protective against different pathogens. 
The development of next generation technologies has enabled the large-scale 
generation of genomic sequences. As genomic sequencing data has become ubiquitous, 
new methods have been developed for identifying regions of the genome that may have 
undergone selection. Most of the tests of selection either search for genomic regions with 
decreased sequence variability as a consequence of selection favoring certain 
haplogroups, or search for genomic regions that differ significantly between two 
populations or species.  
Identifying the genomic footprints of selection 
Tests for identifying the genomic "footprints" of selection can be sub-divided into 
those using inter-species comparisons and those using intra-species population-based 
comparisons. There are three types of interspecies tests, which can sometimes detect 
selection that occurred millions of years ago in humans (Oleksyk et al. 2010). The first 
method for detecting selection is called phylogenetic shadowing. Selection tends to 
preserve functional gene regions whereas non-functional regions experience higher 
effective rates of change. Divergence of homologous segments can be compared between 
species. Regions with a lower divergence than the genome-wide average suggest either 
purifying selection or past actions of positive selection (Oleksyk et al. 2010). For 
example, the 3' untranslated region of the gene SLC16A2 (XPCT) from human, mouse, 
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and tammar wallaby were compared (Wakefield et al. 2003). The human/mouse 
comparison proved to be similar across the region and differences in localized regions of 
functional constraint were masked. When human/wallaby and mouse/wallaby 
comparisons were made, local regions of high similarity were found, suggesting these 
regions were functionally constrained (Wakefield et al. 2003).  
The second method for detecting selection uses the rate of function-altering 
mutations. In regions of the genome that have been under Darwinian selection, there tend 
to be high levels of function-altering mutations for one species when the homologous 
region is compared to another species. Genomic regions under Darwinian selection will 
tend to have higher levels of non-synonymous mutations relative to synonymous 
mutations, while regions under purifying selection have lower relative levels of non- 
synonymous to synonymous mutations. This ratio, often referred to as dN/dS has been 
used extensively to find gene regions under selection. For example, in a positively 
selected domain in the gene coding for the TRIM5α protein, the dN/dS ratio between 
human and rhesus monkey is extraordinarily high (Sawyer et al. 2005). The TRIM5α 
protein plays a crucial role in the primate anti-retroviral defense mechanism, thus the 
gene may be under selective pressure caused by viral pathogens (Pertel et al. 2011).  
The third test of selection compares interspecies divergence to intraspecies 
polymorphism. Under neutrality, the proportion of non-synonymous and synonymous 
changes at a locus should be similar within and between species. Selection decreases 
variation within a species because a selected allele is transmitted with its haplotype. A 
gene under selection should have a lower ratio of within-species divergence compared to 
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between-species divergence, when compared to neutral loci. One implementation of this 
approach is the Hudson-Kreitman-Aguadé (HKA) test, which found a signature of 
positive selection in a region of the maize gene that causes the plant to form ears instead 
of tassels. The reduced diversity present in this genic region in maize suggested that the 
locus had undergone selection during maize domestication (Wang et al. 1999).  
The five additional types of selection tests (numbered four through eight) look for 
footprints of selection using intra-species comparisons. The fourth method for detecting 
selection looks for a reduction in genetic variation in a chromosomal region. A selective 
sweep occurs when a selected allele "carries" along with it neighboring alleles, if the rate 
of recombination is too low to break up the haplotype carrying the allele. This causes the 
region around the selected allele to show reduced variation in a population. Plasmodium 
falciparum, a parasite that causes malaria, has developed resistance to many drugs 
targeting it. For example, a mutation in the parasite's dihydrofolate reductase gene has 
provided resistance to the drug pyrimethamine. The chromosomal region flanking the 
selected allele has undergone a steep decrease in genetic variation, as measured by 
heterozygosity at STR loci, due to a selective sweep (McCollum et al. 2008). 
The fifth method of detecting selection observes changes in the frequency 
distribution of genetic variation in a genomic region. As mentioned previously, a 
selective sweep decreases variability around a selected site. Following the sweep, most 
new mutations will initially have low frequencies. Thus, a genomic region in which 
genetic variants are present at unusually low frequency may be a signature of positive 
selection. Tajima's D captures this shift in the frequency distribution at a locus. For 
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example, in the previously mentioned Plasmodium falciparum parasite, the apical 
membrane antigen 1 (AMA1) surface protein is used by the human immune system to 
target an antibody response (Polley et al. 2001). A section of the AMA1 gene that codes 
for one domain of the AMA1 protein had high values for Tajima's D, suggesting that it 
has been subject to balancing selection (Polley et al. 2001). Unfortunately, demographic 
changes, such as population expansion may also leave a genomic signature that may not 
be distinguishable from selection using this method (Hammer et al. 2003).  
The sixth method of detecting selection examines differentiation between 
populations, measured using FST. If a selective sweep affects one of two populations, the 
affected population should have decreased variation near the selected locus. FST is a 
measure of variation between populations. Selection is suspected where there is relatively 
greater variation between than within populations. For example the duffy blood locus 
(FY) displays among the highest observed values of FST of any locus in humans. Since a 
homozygote FY*O allele confers complete resistance to one species of the malaria 
parasite, differentiation of the FY*O allele is very high across human groups, for example 
between sub-Saharan Africans, who live where malaria is endemic, and Italians, who do 
not live where malaria is endemic (Hamblin et al. 2000).  
The seventh footprint of selection is extended linkage disequilibrium. A region 
that has recently undergone a strong selective sweep may have many neutral alleles in 
linkage disequilibrium with the beneficial mutation, if recombination has not had 
sufficient time to disrupt the haplotype. In North American wolves, the allele for 
melanism was found to have remarkably long haplotypes, suggesting that the haplotype 
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has been under strong selection and is of recent origin in the wolf population (Anderson 
et al. 2009). The haplotype was found to be similar to the haplotype for melanism in 
domesticated dogs, suggesting that it had undergone selection following its introgression 
from dogs into North American wolves (Anderson et al. 2009).  
The eighth and final signature of selection is an elevated admixture contribution 
from one of two ancestral lineages within an admixed population. If a disease-causing 
gene in an admixed population originated within one of the ancestral lineages, then 
genomic regions from the ancestral population more susceptible to the disease should be 
over-represented in individuals with the disease, compared to individuals without the 
disease. Admixture mapping of Puerto Ricans uncovered a region in chromosome 6 with 
relatively high levels of African ancestry and Native American ancestry, and relatively 
decreased levels of European ancestry. The region harbors the human leukocyte antigen 
(HLA) loci involved in immune function (Tang et al. 2008a). It is possible that the 
European HLA alleles were less well adapted to tropical pathogens. 
Methods to examine signatures of selection in the Biaka 
 In order to test the hypothesis discussed in Chapter 1, I would need to search for 
AIDS restriction genes within genomic regions under potential selection in the Biaka. 
One method that seemed appropriate was software that I had previously assisted in 
developing, which searches for signatures of selection using a test that examines both 
population differentiation (method six, above) and local reduction in genetic variation 
(method four, above) (Oleksyk et al. 2008; Oleksyk et al. 2010). This method is described 
in greater detail below. 
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 We also sought to mine information from two previous studies that had looked for 
signatures of selection in the Biaka using the HGDP genotypes, sometimes combining 
these genotypes with additional genotyping. Both studies had examined the Biaka and 
each study provided a list of genes under putative recent selection. However, these lists of 
genes had not been cross-checked for the presence of ARGs or HDFs. 
 In one of these studies, Pickrell and colleagues used the integrated haplotype 
score (iHS) method, which looks for extended haplotype homozygosity (EHH) (see 
above) (Voight et al. 2006; Pickrell et al. 2009). For each SNP, the ancestral state is 
calculated from either dbSNP or by alignment with the chimpanzee genomic sequence. 
For every SNP with ancestral state information and minor allele frequency greater than 
5%, integrated haplotype homozygosity (iHH) for the ancestral and derived allele are 
independently calculated. To calculate each of the two iHH value for each SNP, the 
integral of the EHH away from the SNP is calculated until EHH reaches 0.05. EHH at a 
given distance from the core haplotype was defined as the probability that two randomly 
chosen chromosomes carrying the core haplotype of interest were identical by descent, 
measured by the homozygosity at all SNPs for the entire interval from the core region to 
that point. The unstandardized iHS had been calculated by taking the log-ratio of the 
ancestral iHS, which is subsequently standardized so that the mean is 0 and standard 
deviation is 1 (Voight et al. 2006). Using this method, the iHS score was calculated for 
the Biaka using genomic information (Pickrell et al. 2009). We examined their results for 
loci with the top 1% of iHS scores in the Biaka genome, to look for ARGs and HDFs that 
fell into this category (see Chapter 3).  
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 In the same study, another test of selection that had been run using Biaka 
genomes was the cross-population extended haplotype homozygosity (XP-EHH) test 
(Pickrell et al. 2009). The test was originally developed by Sabeti and colleagues for 
analysis of data from the International HapMap project, which provided approximately 
two million genotypes for each of 240 individuals across four populations in three 
continents (Sabeti et al. 2007). Comparing EHH across populations affords this method 
greater power to detect selective sweeps where one allele has reached or has nearly 
reached fixation in one population, but remains polymorphic in another population. This 
method first calculates the EHH across the genome of each population. The XP-EHH test 
detects SNPs that are fixed or near fixation in one population, but variable in the other 
population. Given a pair of populations, the process considers one SNP, labeled the 'core 
SNP', and one direction away from the core SNP at a time. In the direction away from the 
core SNP under consideration, a comparison SNP is found with the EHH value relative to 
the core SNP closest to 0.4. The integral of the EHH for every SNP between this 
comparison SNP and the core SNP is calculated. The XP-EHH value is the log-ratio of 
the integrals between the two populations (Sabeti et al. 2007). The XP-EHH score had 
been calculated for the Biaka by comparing them to the Bantu (Pickrell et al. 2009) and 
we looked for genomic regions in the top 1% of XP-EHH scores that contained ARGs 
and HDFs (see chapter 3). 
 In a separate study, Lopez Herraez (2009) used a modified lnRsb test of selection 
on a subset of the Biaka genomes from the HGDP. The modified lnRsb method is similar 
to the XP-EHH method, but requires fewer individuals to be genotyped. The lnRsb score 
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was calculated for the Biaka by comparing them to the average values of six sub-Saharan 
African populations (Tang et al. 2007; Lopez Herraez et al. 2009). We examined the 
genomic regions that displayed the top 1% of lnRsb scores, for overlap with the genomic 
locations of ARGs and HDFs (see chapter 3). 
Populations examined for signatures of selection 
 As mentioned above, to examine the genome for signatures of selection, I applied 
an approach we developed and validated previously, which identified signatures of 
selection based on low heterozygosity within populations and variance in FST between 
populations (Oleksyk et al. 2008). Using the method of Oleksyk et al. (2008), I examined 
two pygmy populations that have historically resided in communities in the African 
tropical forest: the Biaka of the Central African Republic are a western pygmy 
population; the Mbuti of the Democratic Republic of Congo are an eastern pygmy 
population. Both groups were part of the Human Genome Diversity Project (HGDP)-
Centre d'Etude du Polymorphisme Humain (CEPH) Panel, a collection of lymphoblastoid 
cell lines from 52 human populations (Cavalli-Sforza 2005; Li et al. 2008). In addition to 
the two populations traditionally residing in African tropical forests, I also examined, for 
comparative purposes, three other populations within the HGDP from Africa south of the 
Sahara (Figure 2.1). These populations, like the pygmies, would exhibit high levels of 
genetic diversity and low levels of linkage disequilibrium, relative to non-African 
populations that have been affected by ancestral founder effect(s) during migration out of 
Africa (Li et al. 2008). The three other sub-Saharan African populations examined were 
the Bantu of Kenya, the Mandenka of Senegal, and Yorubans from Nigeria. Data from 
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the HGDP-CEPH panel was not examined for Bantu outside of Kenya or for the San 
from Namibia, since sample sizes for these groups were small. Individuals identified as 
relatives were removed from the dataset (Rosenberg 2006); the final dataset contained 91 
individuals, including 23 Biaka, 13 Mbuti, 11 Bantu from Kenya, 22 Mandenka and 22 
Yorubans.  
Detecting selection using heterozygosity and FST 
 The method of Oleksyk et al. (2008) is based on the observation that after a 
selective sweep, the genomic neighborhood around an adaptive marker would be depleted 
of variation. When a population containing the selected variant is compared to an 
ancestral or divergent population that did not undergo the selection event, the variance for 
the genetic difference between populations (FST) increases across the compared loci. To 
exploit this signature of genomic selection, our approach compared two populations, 
using an unbiased estimate of heterozygosity for each population, calculated using the 
method described by Nei and Roychoudhury (Nei et al. 1974), and combined this 
information with the variance in unbiased FST between the two populations calculated 
using the Weir and Cockerham method (Weir et al. 1984). Moving average windows 
were constructed from adjacent SNPs, each window containing 2 to 32 flanking loci on 
either side of a central SNP (5 to 65 total loci) (Figure 2.2A). For each window, the 
median heterozygosity in each population and the sample variance of FST was calculated. 
The distribution of multilocus values was evaluated against a distribution created by 
unrestricted random sampling of alleles in the same chromosome (Figure 2.2B), using 
allele sets of the same size (Figure 2.2A). The probabilities resulting from the comparison 
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with the resampled distribution were inferred for each of the 33 multilocus windows 
conferred on each locus, and the highest one was reported (λ), along with the 
corresponding window size (Figure 2.2C). 
 We improved this method by implementing the same algorithm in a more efficient 
framework. The original program was written in SAS, which requires an immense 
number of input-output operations, which depend on the computer's hard drive (Oleksyk 
et al. 2008). James Woo rewrote most of the resampling steps of the SAS program in 
C++, which is several orders of magnitude faster, and I wrote several scripts to use that 
program. I established the reliability of the new program written in C++, by comparing 
its output to the original SAS version (Figure 2.3). The programs that were used after the 
sampling step have not changed since the original publication. 
 Since the program of Oleksyk et al. (2008) uses SNP windows of various sizes, 
we needed to ensure that SNP coverage was of sufficient density and homogeneity for the 
genotyped dataset available for the Human Genome Diversity Panel. I wrote a program in 
the statistical language R (R Development Core Team 2010), that created sliding 
windows for the two most extreme window sizes under consideration, 5 and 65 SNPs. 
For each of the two window sizes, the program created a histogram for the number of 
windows observed that spanned a set of chromosomal distances. For the SNP markers 
genotyped in all five of the sub-Saharan Africa populations that were examined in our 
study, a smooth distribution was evident in the histogram (Figure 2.4), suggesting that 
SNPs are evenly distributed across the entire genome for the HGDP dataset. In no case 
did a 65 SNP window extend across a genomic region longer than ca. 1000 kb. 
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 Having established that SNP coverage was sufficiently dense for the HGDP, I 
applied the method of Oleksyk (2008) to pairwise comparisons of the five African 
populations. For each window, the median heterozygosity for each population and the 
sample variance of FST were calculated as described by Oleksyk et al. (2008). The 
estimates of multilocus values were evaluated against a distribution created by 
unrestricted random sampling of values across the chromosome in multilocus windows of 
the same size (Oleksyk et al. 2008). Extreme values of fractional rank were predicted 
using curvilinear regression to extend estimates below 1x10
-7
 attainable by fitting the 
observed data in the most extreme 2.5% SNP frames into their resampled distributions, 
which was referred to as λ (Oleksyk et al. 2008). For each pair of populations, the 
maximum likelihood of λ was selected for all windows centered on each SNP. Windows 
centered on SNPs where at least two of the three scores were in the top 2.5% were 
concatenated with overlapping or adjacent windows fulfilling the same criteria.  
 For joined windows, the category of selection was determined by the set of 
calculated scores that exceeded the 2.5% cutoff in any independent (before 
concatenation) window (Oleksyk et al. 2008). If median heterozygosity in one population 
and variance of FST were both in the top 2.5%, then a signature of “new” selection (post-
dating the split between the two populations) was inferred for the population. If the 
threshold of being in the top 2.5% of genomic values was exceeded by median 
heterozygosity in both populations, but was not exceeded by the variance in FST, then a 
signature of “old” selection (pre-dating the split between the two populations) was 
inferred. If the threshold of being in the top 2.5% of genomic values was exceeded by 
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median heterozygosity in both populations, and was exceeded also for the variance in 
FST, then a signature of “new” selection was inferred for both populations.  
 Using this methodology, the fraction of the genome detected under selection 
between pairs of populations was between 1.58% and 2.55% (Table 2.1), and thus 
relatively similar across comparisons. The comparison between Biaka and Mbuti pygmy 
groups produced the lowest estimate for proportion of the genome showing signatures of 
selection, a total of 1.6% (Table 2.1). In this comparison, new selection in the Biaka 
totaled 0.33% of the autosomes, new selection in Mbuti 0.40%, new selection in both 
populations 0.22%, and old selection 0.63% (Table 2.1). Having determined the regions 
of the genome that were under putative selection in the Biaka and other African groups, 
using the method of Oleksyk (2008), we were now prepared to compare the genomic 
locations of AIDS restriction genes to the genomic regions showing signatures of 
selection, to determine whether a disproportionate number of ARGs may have been under 
selection in the Biaka.  
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Figures and Tables 
 
Figure 2.1. Map showing the geographic locations of five human populations in sub-
Saharan Africa. These populations are each part of the Human Genome Diversity Panel 
and have been extensively genotyped (Cavalli-Sforza 2005; Li et al. 2008). Between each 
possible pair of populations, we conducted scans to identify regions potentially under 
selection. The Biaka and Mbuti are pygmy groups in the Central African Republic and 
the Democratic Republic of Congo, respectively. Non-pygmy African populations 
examined include the Bantu in Kenya, Mandenka in Senegal, and Yoruba in Nigeria.  
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Figure 2.2. Illustration of the method of Oleksyk et al. (2008) for analyzing genomic 
regions for signatures of selection. We used this method to compare pairs of African 
populations to examine their genomes for signatures of selection. The method had 
originally been developed by us to compare African American and European American 
genomes, as shown in this figure. (A) Sampling and resampling process: (Top) We 
selected five adjacent SNPs at the beginning of a single chromosome and computed 
median heterozygosity in Europeans (HEA), median heterozygosity in African Americans 
(HAA), and variance in FST between the two populations (S
2
FST) for the group of adjacent 
alleles, then moved the window sequentially downstream, one SNP at a time (observed 
values). (Bottom) To establish the baseline, we randomly resampled with replacement 
one million groups of five random SNPs on the same chromosome and computed HEA, 
HAA and S
2
FST (random values). (B) Determining observed and random distributions of 
HEA, HAA and S
2
FST: (Top) We built a frequency distribution for each chromosome using 
observed values; (Bottom) we built a frequency distribution and assigned fractional rank 
values to the distribution of random values. (C) Superimposing the distributions to derive 
fractional rank values: the two distributions were combined and each observed value 
assigned a fractional rank from the closest larger random value. The same computation 
was done for all 31 SNP window group sizes (N=5, 7, 9 … 65). For each SNP, the lowest 
mean value for HEA was chosen from the 31 windows of size 5 to 65, and plotted across 
the length of each chromosome in cM. Likewise, the same derivation was applied to HAA 
and S
2
FST. Figure from (Oleksyk et al. 2008).  
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Figure 2.2 (cont.)
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Figure 2.3. Consistency of results obtained between SAS and C++ implementations 
of the method of Oleksyk (2008). The SAS implementation had been used to generate 
the analyses presented in Oleksyk et al. (2008), while the current analyses were generated 
using a faster program implemented in C++. This figure shows the correlation of values 
obtained using C++ (x-axis) and SAS (y-axis). Both programs were implementations of 
the method described in Oleksyk et al. (2008). Correlation of each of the unadjusted 
probabilities is shown for one comparison (Biaka v. Mbuti) involving one chromosome 
(11) and one window size (33). Plot (A) shows the Biaka median heterozygosity 
probability, (B) shows the Mbuti median heterozygosity probability, and (C) shows the 
S
2
FST. In each of the plots, rank order was preserved, as would be expected if the results 
were consistent. The correlation was not perfectly linear due to a difference in ranking 
between the two programs: The SAS program assigned the lowest (most extreme) rank to 
all values in a tie, while the C++ program assigned the highest (least extreme) rank. Since 
very few possible values exist for the median heterozygosity, shown in (A) and (B), the 
data points appear to be sparse. A less sparse distribution is evident for S
2
FST in (C). 
Here, very close correlation between the two programs were evident, except at the 
highest (less dense) rankings. 
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Figure 2.3 (cont.) 
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Figure 2.4. Length of genomic regions, in thousands of bases (kb), covered by the 
sliding windows containing 5 and 65 SNPs. The program of Oleksyk et al. (2008) uses 
SNP windows that range in size from 5 to 65 SNPs. We determined the length of 
genome, in kb, that was covered by each window of 5 (top panel) or 65 (lower panel) 
SNPs. (Note: The x-axis differs between the two panels.) For this SNP data, which 
includes all individuals in the five sub-Saharan populations considered in our study, a 
smooth distribution is evident in the histogram, suggesting that SNPs were evenly 
distributed across the entire genome. In no case did a 65 SNP window extend across a 
genomic region longer than ca. 1000 kb. 
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Table 2.1. Proportion of genome showing signatures of selection, for all pairwise comparisons. The fraction of the 
genome that showed signatures of selection when pairs of populations were compared ranged between 1.58% and 2.55%. The 
comparison between Biaka and Mbuti pygmy groups produced the lowest estimate for proportion of the genome showing 
signatures of selection, a total of 1.6%. 
Genomes compared New selection in 
Old selection  Total  
Population 1 Population 2 Population 1 Population 2 Both 1 and 2  
Biaka Mbuti 0.33% 0.40% 
0.22
% 
0.63% 1.58% 
Biaka Bantu 0.30% 0.39% 
0.48
% 
0.61% 1.77% 
Biaka Mandenka 0.42% 0.35% 
0.80
% 
0.58% 2.15% 
Biaka Yoruba 0.49% 0.46% 
0.67
% 
0.57% 2.19% 
Mbuti Bantu 0.39% 0.48% 
0.61
% 
0.37% 1.86% 
Mbuti Mandenka 0.33% 1.28% 
0.35
% 
0.37% 2.32% 
Mbuti Yoruba 0.76% 0.37% 
0.33
% 
0.37% 1.82% 
Bantu Mandenka 0.26% 0.28% 
0.45
% 
1.33% 2.32% 
Bantu Yoruba 0.31% 0.45% 
0.19
% 
0.99% 1.94% 
Mandenka Yoruba 0.43% 0.39% 
0.21
% 
1.52% 2.55% 
“New” selection indicates selection after the divergence of the two populations. 
“Old” selection occurred prior to the divergence of the two populations. 
Proportions are based on physical size (bp not cM) of the genome 
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Chapter 3. Signatures of selection at ARGs in the Biaka  
Introduction 
 Variation in human genes is known to affect susceptibility to HIV-1 and disease 
progression following infection (An et al. 2010). Host genes responsible for differences 
in susceptibility or response to infection are sometimes referred to as AIDS restriction 
genes (ARGs) (O'Brien et al. 2004). Many ARGs have been uncovered through the 
genotyping of cohorts established in the 1980s consisting of large numbers of patients or 
high risk individuals (An et al. 2010) and identified by genetic association analyses of 
candidate gene variants, or by genome-wide association studies (An et al. 2010). Host 
genetic variation in these ARGs has been found to positively or negatively affect HIV 
infection or outcome (O'Brien et al. 2004; An et al. 2010). In addition, human host genes 
required for HIV-1 infection have been identified using small interfering (si) RNA 
knockdown screens conducted on cell lines infected with HIV. Several siRNA studies 
have been independently conducted, each of which involved the knock-down of almost 
every human gene (Brass et al. 2008; Konig et al. 2008; Zhou et al. 2008). Each of the 
studies found over 200 human genes that were candidates for involvement in HIV-1 
infection, designated host dependency factors (HDFs).  
 HIV-1 derives from simian immunodeficiency viruses (SIV) infecting the 
common chimpanzee, Pan troglodytes (Sharp et al. 2010). HIV-1 sequences are 
polyphyletic in humans: each of the four HIV-1 groups present in humans (M, N, O, P) is 
closer in sequence to strains of SIV present in the central African subspecies (P.t. 
troglodytes) of the common chimpanzee than they are to HIV-1 sequences belonging to 
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other human HIV-1 clades (Sharp et al. 2010). This suggests that HIV-1 originated in 
four or more independent cross-species transmissions (Sharp et al. 2010). The natural 
range of the central African chimpanzee comprises the Congolian forest block of Central 
Africa, west of the Congo River, suggesting that the various HIV-1 groups may have first 
infected humans living in this region, subsequently giving rise to the world-wide 
pandemic.  
Archival medical samples collected in Leopoldville (now Kinshasa) during 1959 
and 1960 are the earliest documented evidence of HIV-1 infections in humans (Worobey 
et al. 2008). The diversity of HIV-1 present in these and in subsequently collected 
samples allowed the date of cross-species transmission for HIV-1 clade M viruses to be 
estimated as having occurred between 1884 and 1924 (Worobey et al. 2008). Since SIV 
was present in chimpanzees before this time, and since HIV-1 has crossed the species 
barrier from chimpanzees to humans multiple times, we considered it unlikely that a virus 
known to have repeatedly entered human populations would only begin to do so in the 
past century or two. Furthermore, we hypothesized that the virus may have repeatedly 
crossed the species barrier into local human populations before the current pandemic 
began, but with outbreaks prior to the current pandemic extinguished due to the quick 
susceptibility of immunodeficient individuals to formerly pervasive infectious diseases 
(e.g., smallpox). If immunodeficiency viruses had repeatedly affected human populations 
locally before current pandemic, this may have generated selection pressure for 
resistance, which could be reflected in genomic signatures in the chromosomes of the 
living descendants of the affected populations. 
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I tested this hypothesis by comparing the genomes of Biaka Western pygmies in 
the Central African Republic, a group that has lived within the range of P. t. troglodytes 
for tens of thousands of years (Cavalli-Sforza 1986; Verdu et al. 2009), to the genomes of 
the Mbuti, an Eastern pygmy population in the Democratic Republic of Congo, who live 
outside the range of P. t. troglodytes. Both groups had previously been genotyped for 
~650,000 SNPs (Li et al. 2008). I examined this data for signatures of selection in the 
genomes of the Biaka around host genes involved in HIV restriction (ARGs), or among 
host genes that appear to interact with HIV in studies using cell lines (HDFs).  
Materials and methods 
 I examined two pygmy populations that have historically resided in the African 
tropical forest: the Biaka of the Central African Republic are a Western Pygmy 
population; the Mbuti of the Democratic Republic of Congo are an Eastern pygmy 
population. Both groups were part of the Human Genome Diversity Project (HGDP)-
Centre d'Etude du Polymorphisme Humain (CEPH) Panel, a collection of lymphoblastoid 
cell lines of 52 geographically diverse human populations (Figure 1.7) (Cavalli-Sforza 
2005; Li et al. 2008). In addition to the two populations residing in African tropical 
forests, we also examined, for comparative purposes, three other human populations 
within the HGDP from Africa south of the Sahara. These populations, like the pygmies, 
exhibit high levels of genetic diversity and low levels of linkage disequilibrium, relative 
to the non-African populations that have been affected by ancestral founder effect(s) 
during migration out of Africa (Li et al. 2008). The three other sub-Saharan African 
populations examined were the Bantu of Kenya, the Mandenka of Senegal, and Yorubans 
52 
from Nigeria (Figure 1.7). Data from the HGDP-CEPH panel was not examined for 
Bantu outside of Kenya or for the San from Namibia, since sample sizes for these groups 
were small. Individuals identified as relatives were removed from the dataset (Rosenberg 
2006); the final dataset contained 91 individuals, including 23 Biaka, 13 Mbuti, 11 Bantu 
from Kenya, 22 Mandenka and 22 Yorubans. 
 I used the SNP data for the HGDP-CEPH Panel, a dataset containing 938 
individuals genotyped on the Illumina 650K platform (Li et al. 2008). Using the 
standardized subset of the HGDP data, genotypes for 644,258 autosomal SNPs were 
available (Rosenberg 2006). Chromosomal positions for the SNPs were provided by the 
HGDP release for NCBI Human Genome build 36.1 and map distances in centiMorgans 
(cM) were calculated using those positions and recombination estimates provided by the 
HapMap project phase I+II (Frazer et al. 2007).  
 AIDS restriction genes (ARGs) were defined as host genes with variation that has 
been shown to affect HIV infection or outcome (O'Brien et al. 2004; An et al. 2010). A 
total of 45 genes at 26 loci were classified as ARGs based on published research reports, 
as detailed in chapter 1 (Table 1.1). HIV Dependency Factors (HDFs) were identified 
based on published results of siRNA knockout panels designed to uncover genes whose 
depletion significantly reduces the infection and/or replication ability of HIV (Brass et al. 
2008; Konig et al. 2008; Zhou et al. 2008); or based on a published NIH listing of human 
host genes that may interact with HIV (Fu et al. 2009). I identified any ARGs or HDFs 
that overlapped completely or partially with the regions identified by our genomic scans 
comparing pairs of African populations as displaying signatures of selection, using a 
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program that I wrote in R (R Development Core Team 2010). Each ARG and HDF was 
matched to its chromosomal location using the University of California at Santa Cruz 
(UCSC) genome browser (Fujita et al. 2010). The R program returned any ARG or HDF 
with one or more base-pairs that overlapped a region with a signature of selection. ARGs 
and HDFs found in regions of selection between all pairs of populations are listed in 
Table 3.2.  
 For individual genes of interest, probability plots of within-population 
heterozygosity and between-population variance in FST around individual loci were 
constructed using the R statistical software package (R Development Core Team 2010), 
centering on the x-axis a genomic segment that was three times the genetic (cM) size of 
the region found to display a signature of selection. The y-axis corresponded to the 
maximum value at each SNP, across the window sizes used, of the λ scores derived from 
maximum likelihood of sliding windows of heterozygosity in each population, and of 
variance in FST (S
2
FST) between the two populations. The genes of interest were mapped 
onto the figure using positions based on the UCSC genome browser build hg18 (Fujita et 
al. 2010). 
 The plot comparing the number of genes contained in each region under putative 
selection and the length of the region under putative selection was also constructed using 
the R software package (R Development Core Team 2010). For each region under 
putative selection, genes overlapping with the region were counted, with gene positions 
provided by the UCSC human genome build 18 (Fujita et al. 2010). The counts of genes 
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were plotted along with the length of each region under putative selection (in number of 
SNPs or in kb). 
 I incorporated the results of other selection scans, described in detail in chapter 2, 
that had examined SNP genotypes among the Biaka pygmy population. Results of scans 
using integrated haplotype score (iHS) and cross population extended haplotype 
homozygosity (XP-EHH) tests had relied on a sliding window size of 200 kb to identify 
genes under regions showing signatures of selection, with increments of 100 kb or 200 kb 
used for alternative analyses (Pickrell et al. 2009). We identified ARGs and HDFs among 
genes identified as under potential selection in the Biaka by a previous study that applied 
these methods to the HGDP SNP dataset (Pickrell et al. 2009). Another study had 
genotyped five individuals from each HGDP population, including five Biaka, using the 
Affymetrix GeneChip Human Mapping 500 K array set, concatenating this dataset with 
that of the Illumina chip (Lopez Herraez et al. 2009). Signatures of selection had been 
inferred from this data using a modified lnRsb approach, which is similar to the XP-EHH 
method (Lopez Herraez et al. 2009). We identified ARGs and HDFs among the genes 
previously reported as displaying signatures of selection in the Biaka by this method as 
well (Lopez Herraez et al. 2009).  
Results 
 I looked for evidence of selection by comparing public SNP datasets between 
Biaka Western pygmies and Mbuti Eastern pygmies. We also ran selection scans using 
three other African populations (Figure 2.1), running genomic comparisons between each 
pair of African populations. The genotyped SNP density was found to be sufficient for 
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the method used by this study, as sparse windows extending more than 1 cM were found 
not to be present in the genomes (Figure 2.4). To look for genomic signatures of 
selection, we used a method that relied on multilocus heterozygosity within and FST 
variance between populations, as described in chapter 2 (Oleksyk et al. 2008).  
 I examined genomic regions identified as showing signatures of selection for the 
presence of AIDS restriction genes (ARGs), human genes in which polymorphisms are 
known to affect HIV infection or outcome. These ARGs were listed and described in 
Table 1.1. Across the five sub-Saharan Africa populations examined (Bantu, Biaka, 
Mandenka, Mbuti, Yoruba), only five of the ten pairwise comparisons detected any 
region with signatures of selection overlapping an ARG (Figure 3.1). Signatures of 
selection were detected in a total of eight cases involving four distinct ARGs (Figure 3.1). 
Remarkably, seven of these eight cases where signatures of selection overlapped with the 
genomic position of an ARG involved evidence for old or new selection occurring in the 
Biaka (Figure 3.1). 
 One of the identified ARGs was TRIM5, a gene that plays a pivotal role in the 
primate antiviral defense system (Stremlau et al. 2006). TRIM5 was found in a genomic 
region showing the signature of ‘new’ selection in the Biaka when compared with each of 
three populations: Bantu, Mandenka, and Mbuti. TRIM5 was also in a genomic region 
displaying a signature of ‘old’ selection when Bantu was compared with Mandenka, 
which was the only case of an ARG under potential selection among comparisons that did 
not involve the Biaka (Figure 3.1).  
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 I looked for previously published SNPs (Javanbakht et al. 2006) in TRIM5 linked 
to HIV-1 risk in the Biaka genotypes from Li et al. (2008), Jakobsson et al. (2008), and 
Lopez Herraez et al. (2009). For the former two studies, I used the SPSmart software to 
find matching SNPs (Amigo et al. 2008). For the latter study, I manually read the raw 
data output. I found that a protective allele in the TRIM5 SNP rs10838525, that results in 
a codon-changing mutation in the translated TRIM5-alpha protein, was in highest 
frequency in Biaka compared to all other African populations. The protective allele, T, 
was found in 11.4% of Biaka, compared to 9.1% of the next highest African population, 
the Mandenka. 
 Another ARG, TSG101, which has been shown to influence the rate of AIDS 
progression (Bashirova et al. 2006), was in a genomic regions showing the signature of 
old selection when the Biaka were compared to Mandenka. The ARG CUL5, for which 
genetic variation has been found to affect the rate of AIDS progression in patients (An et 
al. 2007a), was found in a region that displayed a strong signature of ‘new’ selection in 
Biaka when compared with Mbuti pygmies. Finally, the ARG PARD3B was in a genomic 
region showing the signature of ‘old’ selection when Biaka were compared with Mbuti or 
Yoruba. Variation in PARD3B has been found to have a strong association with AIDS 
progression by a GWAS study (Troyer et al. 2011). 
 Likelihood scores for heterozygosity and variance of FST were plotted for the two 
ARGs that were found to be within regions demonstrating a signature of new selection in 
the Biaka pygmies when compared to Mbuti pygmies (Figure 3.2). Both CUL5 and 
TRIM5 showed extremely low values of heterozygosity (high peaks) in the Biaka, with 
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high values (high peaks) for the variance of FST in the genomic regions around each gene 
(Figure 3.2). For CUL5, the signature of selection was among the highest detected for the 
Biaka-Mbuti comparison. CUL5 was included in the region of the genome that showed 
the tenth strongest signal of new selection in Biaka in the pairwise comparison involving 
the two pygmy groups. Furthermore, I found that the region under putative selection that 
included CUL5 was among the longest (in kb or SNPs) detected using this method 
(Figure 3.3). This may be a further indication of strong or recent selection of this region, 
since strong or recent selection can produce a signature across a longer region of the 
genome (Oleksyk et al. 2010). I also determined that genomic region under putative 
selection around CUL5 does not appear to have unusually low or high SNP coverage 
given the length of the region (Figure 3.3), an indication that unusual SNP densities 
would not be distorting any signal.  
For TRIM5, the other ARG detected in a region under putative recent selection in 
the Biaka, the length of the region displaying a signature of selection was shorter and the 
signatures of selection were not as strong as for CUL5 (Figures 3.2 and 3.3). For TRIM5, 
I was able to examine the HGDP individuals for a mis-sense mutation in a SNP 
(rs10838525) associated with protective effects against HIV-1 (Javanbakht et al. 2006). 
This mutation is more common among non-African than African populations, although 
among the African populations examined by our study, I found that protective SNP was 
found to have a higher frequency in the Biaka compared to other African populations (Li 
et al. 2008).  
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For PARD3B, a significant correlation has been found in European Americans 
between the rare T allele for SNP rs10185378 (a missense mutation in the coding region) 
and slower AIDS progression (Troyer et al. 2011). We examined the 52 populations 
genotyped by HGDP-CEPH for this SNP. Among the 52 populations, the beneficial T 
allele was found to be most common in Yorubans (36%), third-most common in Mbuti 
(19%), and fourth-most common in Biaka (18%). Unfortunately, I found that the degree 
of SNP overlap between cohort studies and HGDP genotyping was not sufficient to 
examine the Biaka for protective SNPs for CUL5. 
The regions identified as under putative selection in comparisons between Biaka 
and Mbuti were also examined to identify which of 2142 genes previously identified as 
HDFs or as genes that potentially interact with HIV in the cell would also overlap 
genomic signatures of selection. A total of 55 HDFs were found to be under some type of 
putative selection in Biaka or Mbuti. These genes are listed in Table 3.1. Similar analyses 
for ARGs and HDFs under regions of the genome showing signatures of selection for 
pairwise comparisons across all five African populations are also shown in Table 3.3. 
  We examined results from previous tests of selection (described in detail in 
chapter 2) conducted on Biaka genomes by Pickrell et al. 2009 (Pickrell et al. 2009) and 
Lopez Herraez et al. 2009 (Lopez Herraez et al. 2009). Pickrell et al. (2009) used the 
same HGDP SNP genotyping data as the current study to examine signatures of selection 
using two methods: cross population extended haplotype heterozygosity (XP-EHH) 
(Sabeti et al. 2007) and integrated haplotype score (iHS) (Voight et al. 2006). Lopez 
Herraez (Lopez Herraez et al. 2009) genotyped a subset of individuals from the HGDP-
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CEPH panel using a different set of SNPs and used the additional SNP genotypes in 
combination with the HGDP-CEPH panel genotyped using the Illumina 650K SNP array 
to identify regions showing signatures of selection using the lnRsb method, which is 
similar to the XP-EHH method (see Chapter 2). We identified ARGs and HDFs among 
the genes found to be under potential selection in Biaka by these studies, and listed them 
in Table 3.1. None of the genes identified by Lopez Herraez et al. 2009 as under potential 
selection in the Biaka was an ARG. However, Pickrell et al. had included the ARG 
TSG101 (also found in Table 3.2) in the set of genes identified as under potential 
selection in the Biaka. Variation in TSG101 has been associated with differences in AIDS 
progression rates (Bashirova et al. 2006), but the SNPs used in that study did not overlap 
sufficiently with those of the current study for beneficial or detrimental alleles to be 
identified in the Biaka. 
Discussion 
 We considered the hypothesis that HIV-1 may have crossed the species barrier 
into local human populations repeatedly and been extinguished prior to the current 
pandemic, perhaps due to quick susceptibility of immunodeficient individuals to formerly 
pervasive infectious diseases (e.g., smallpox). If immunodeficiency viruses had 
repeatedly crossed the species barrier, this may have led to selection for HIV resistance 
among human forest populations, which could be reflected in the genomic signature of 
their living descendants. To test this hypothesis, we compared the genomes of Biaka 
(Western pygmies) in the Central African Republic, a group that has lived within the 
range of P. t. troglodytes for thousands of years, to the genomes of the Mbuti, an Eastern 
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pygmy population in the Democratic Republic of Congo, who live outside the range of P. 
t. troglodytes. These two pygmy groups have been separated for approximately 20,000 
years (Destro-Bisol et al. 2004; Patin et al. 2009; Batini et al. 2011). We also examined 
the genomes of three other African groups who live in regions outside the range of P. t. 
troglodytes, and have been separated from pygmies for more than 50,000 years (Batini et 
al. 2011). We used the genome-wide SNP data to conduct pairwise comparisons of five 
African populations to identify genomic regions showing potential signatures of selection 
(Figure 3.1). The regions under putative selection were examined for ARGs (Table 1.1), 
with the ARGs CUL5 and TRIM5 found to be within regions of putative recent selection 
among the Biaka Western pygmies, with CUL5 demonstrating a very strong signal of 
selection (Figures 3.2 and 3.3).  
The ARG CUL5 codes for the cullin 5 protein, which is recruited by HIV-1 viral 
infectivity factor (vif) to form a protein complex that functions as an ubiquitin ligase. The 
complex that includes CUL5 targets and suppresses the anti-viral activity of human 
apolipoprotein B mRNA editing enzyme APOBEC3G, which is a crucial inhibitor of 
HIV-1 (Malim 2009). CUL5 polymorphisms in African Americans have been associated 
with more rapid CD4+ T cell loss following HIV-1 infection in humans (An et al. 2007a). 
Two SNPs in this gene have been associated with accelerated progression to AIDS while 
one SNP has been associated with delayed progression to AIDS (An et al. 2007a). In 
addition, the dominant negative mutant CUL5∆Nedd2 cannot be appropriated by HIV-1 
vif to form a complex to degrade of the host antiviral protein APOBEC3H (Zhen et al. 
2010). Although we found CUL5 under strong selection in the Biaka, the overlap in SNP 
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data between the current study and analyses of CUL5 in HIV-1 cohort studies was not 
sufficient to determine whether Biaka pygmy genotypes would likely be protective. 
 TRIM5-alpha, the largest alternative splicing protein isoform of the TRIM5 gene, 
is essential for primate retroviral capsid recognition and anti-HIV-1 activity (Song et al. 
2005). TRIM5-alpha is a RING domain-E3 ubiquitin ligase that specifically recognizes 
and prematurely de-coats the HIV-1 capsid to deactivate the virus (Stremlau et al. 2006). 
It has been demonstrated to have a secondary function of promoting innate immunity 
signaling after detection of the HIV-1 capsid particle (Pertel et al. 2011). TRIM5-alpha, 
in conjunction with the UBC13-UEV1A heterodimer, catalyzes the synthesis of 
unattached K63-linked ubiquitin chains to activate TAK1 kinase and stimulate AP-1 and 
NFκ-B signaling. Interaction with the HIV-1 capsid lattice enhances the UBC13-
UEV1A-dependent E3 activity of TRIM5-alpha (Pertel et al. 2011). Interestingly, a rare 
allele of TRIM5 has previously been detected in the Baka Western pygmies of 
southeastern Cameroon (the current study examined the Biaka Western pygmies of the 
Central African Republic). That allele, found as a heterozygote in 4% of the Baka 
pygmies results in a truncation of the TRIM5-alpha peptide lacking the functionally 
important SPRY domain, which would have detrimental effects for individuals infected 
by HIV-1 (Torimiro et al. 2009). By contrast, in our survey of pygmies we found that a 
protective mis-sense mutation in TRIM5 (rs10838525) (Javanbakht et al. 2006), which 
would have beneficial effects for individuals infected by HIV-1, was in the highest 
frequency in Biaka compared to other African populations. 
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The ARG TSG101 was also found to be under potential recent selection in Biaka 
compared with Mandenka, while we discovered that a previously conducted haplotype 
homozygosity test had identified TSG101 as within the genomic regions demonstrating 
the 8th strongest signal of selection in Biaka (Table 3.2). TSG101 encodes for a protein 
that is commandeered by HIV-1 to facilitate its budding process from an infected cell 
(Bashirova et al. 2006). Unfortunately, the overlap in SNP data between the current study 
and analyses of TSG101 in HIV-1 cohort studies was not sufficient to determine whether 
Biaka pygmy genotypes would likely be protective.  
 The ARG PARD3B, a homolog of the C. elegans cell polarity determinant gene, 
was found in a region of old selection when the Biaka were compared with the Mbuti and 
when the Biaka were compared with Yorubans. Recently, a genome wide association 
study found significant correlation in European Americans for a rare allele and delayed 
AIDS progression. Using the HGDP genotype data, this allele is most common in 
Yorubans, third-most common in Mbuti, and fourth-most common in Biaka (Li et al. 
2008) among the 52 human populations of the HGDP. 
 Although it is intriguing to detect signatures of selection around several AIDS 
restrictions genes in the Biaka Western pygmies, our findings must be qualified for 
several reasons: first, using any of the methods described, there would be a degree of 
uncertainty and false positive signals in determining the regions of the genome under 
selection; some signals may result from other demographic factors or from drift. Second, 
there is a degree of uncertainty regarding the identification of genes as ARGs or HDFs. In 
particular, the genes identified as HDFs show little overlap across different studies (Brass 
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et al. 2008; Konig et al. 2008; Zhou et al. 2008; An et al. 2010) as detailed in chapter 1, 
with only three human genes identified by all three knock-down studies, and 40 other 
genes detected by at least two of the studies (Brass et al. 2008; Konig et al. 2008; Zhou et 
al. 2008). Likewise, some genes previously identified as ARGs by candidate gene 
analyses have not been verified by Genome-Wide Association Studies (GWAS) (An et al. 
2010). Third, many of the regions of the genome that show signatures of selection contain 
multiple genes (Figure 3.3), and these non-ARG genes could be responsible for the signal 
of selection. Fourth, not all of the signals of selection have been comprehensively shown 
to represent increased frequencies of protective alleles in the Biaka, as would be expected 
if HIV-1 was selecting for protective alleles. Fifth, selective pressure on host genes that 
interact with retroviruses would not necessarily be due to HIV-1. Other retroviruses may 
have affected Central African populations and shaped their genomes. For example, the 
Human T-cell lymphotrophic virus types 1 and 2 (HTLV-1/2) are endemic in some 
African pygmy groups, such as the Bakola in southern Cameroon and the Mbuti (Efe) in 
the Democratic Republic of Congo (Vandamme et al. 2000; Mauclère et al. 2011). In the 
Biaka pygmies, one individual out of 106 tested was found with HTLV-1 antibodies 
(Gessain et al. 1993). More recently a strain of HTLV closely related to STLV-3 has been 
found in a Cameroon Baka pygmy (Calattini et al. 2009). In addition, blood samples of 
hunters in south-eastern Cameroon found evidence of cross-species transfer of simian 
foamy virus (SFV) in several bushmeat hunters (Wolfe et al. 2004b). Finally, the Pan 
troglodytes endogenous retrovirus (PtERV1) is endogenous in the genomes of both 
chimpanzee and gorilla genomes, but has not been found in humans (Yohn et al. 2005). 
64 
Differences in the ARG TRIM5 between humans and chimpanzees may have protected 
ancient humans from PtERV1 which consequently made humans more vulnerable to 
HIV-1-infection (Kaiser et al. 2007). Thus multiple pathogens may have affected ARGs 
in African populations. 
 Nonetheless, our finding that four ARGs show potential signatures of selection in 
the Biaka, and that the Biaka carry ARG alleles that may be protective against HIV-1, 
remains intriguing, Especially since several of the ARGs in our table of interest would 
not have been detected as under putative selection using our method, such as HLA and 
KIR, due to the high density of recombination hotspots around those loci. Furthermore, 
several previous studies have reported  that African pygmies carry protective copies of a 
number of other ARGs. The CC chemokine ligand 3-like 1 (CCL3L1) protein binds to 
the HIV coreceptor CCR5 (Gonzalez et al. 2005; An et al. 2010). Copy number variation 
of the CCL3L1 gene is present among both European Americans and African Americans. 
Higher copy numbers within each group for CCL3L1 gene have been associated with 
protection against HIV-1, possibly due to competition with the CCR5 receptor used by 
HIV-1 to enter cells (Gonzalez et al. 2005). The Biaka have the second highest copy 
number of CCL3L1, and the Mbuti the fourth highest copy number, among 57 human 
populations examined across the world (Gonzalez et al. 2005). However, it should be 
noted that the protection afforded by increased CCL3L1 copy number was not confirmed 
by some follow-up studies (Bhattacharya et al. 2009).  
 Additionally, the CCR5 haplotype most commonly found in African pygmies is 
associated with delayed HIV-1 disease progression (Gonzalez et al. 1999). Models have 
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suggested that among pygmies, with both high CCL3L1 copy number and protective 
CCR5 alleles, the spread of HIV-1 might be minimal due to protective genotypes present 
within their populations (Kulkarni et al. 2008). Although we did not detect selection at 
CCR5, some of the ARGs in our table of interest would not have been detected using our 
method. 
 African pygmies are susceptible to HIV-1, which derives from contact with other 
human groups, as there is no evidence for ongoing cross-species transmission from non-
human primates (Gonzalez et al. 1987; Zekeng 2001; Ndembi et al. 2003; Gonzalez et al. 
2005). Several surveys of bushmeat hunters in the tropical forest of Central Africa have 
found hunters to be infected by a number of viruses that likely resulted from direct 
interspecies transmission from the non-human primates being hunted. However, direct 
transmission of immunodeficiency viruses from non-human primates has not been 
detected among bushmeat hunters (Goepfert et al. 1996; Wolfe et al. 2004a; Wolfe et al. 
2004b; Switzer et al. 2008). However, these findings do not rule out historical 
interspecies transmissions of immunodeficiency viruses from chimpanzees to humans, as 
at least several such interspecies transmissions within the past two centuries are believed 
responsible for the current HIV-1 pandemic (Sharp et al. 2010). 
 Given previous findings and based on our own results, we cannot reject the 
hypothesis that Western pygmies may have been subject to selection for resistance to 
HIV-1. We found evidence for signatures of recent selection in the Biaka Western 
pygmies in genomic regions including the ARGs CUL5, TRIM5, and TSG101; and for old 
selection in the genomic region containing the ARG PARD3B. For two of these genes, 
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TRIM5 and PARD3B, SNPs that may be beneficial against HIV-1 were detected among 
pygmies. Previous researchers have reported a high copy number for CCL3L1 (associated 
with favorable HIV outcome) in pygmies, while both Biaka and Mbuti pygmies have 
high frequencies of the protective, ancestral CCR5 HHA haplotype (Kulkarni et al. 2008). 
Given these findings, the hypothesis that HIV-1 may have shaped the genomes of 
Western pygmies appears to merit further investigation.  
 
  
67 
Figures and Tables 
Figure 3.1. AIDS restriction genes (ARGs) under potential selection. ARGs under 
potential selection were revealed by pairwise genomic comparisons of African 
populations. The genomic locations of 26 ARG loci were compared to regions of the 
genome identified as potentially under selection. ARGs potentially under selection are 
indicated by the different lines or arrows connecting each pair of populations used in 
genomic comparisons, with the type of selection indicated by the key. “New” selection in 
a local population indicates selection after the divergence of the two populations. “Old” 
selection is common selection that occurred prior to the divergence of the two 
populations. Among ten pairwise comparisons, five yielded evidence of selection, of 
which four involved the Biaka. Signatures of selection were detected in a total of eight 
cases involving four distinct ARGs. Interestingly, seven of these eight cases showing 
evidence of selection for an ARG involved the Biaka population. There was evidence for 
selection in the Biaka for CUL5, PARD3B¸ TRIM5, and TSG101. There was only one 
case of an ARG under potential selection among comparisons that did not involve the 
Biaka, as TRIM5 was found to be under old selection when Bantu and Mandenka were 
compared. 
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Figure 3.2. Probability plots Biaka and Mbuti for two ARGs under recent selection. 
The x-axes show chromosomal positions for CUL5 (panel A) and TRIM5 (panel B). The 
y-axes map the negative log probability for maximum likelihood scores across moving 
windows of SNPs, used to examine the genome for signatures of selection (Oleksyk et al. 
2008). Note that the x- and y-axes for the two genes use different scales. The lines 
represent values calculated for heterozygosity in Biaka (blue, or the darkest line) and 
Mbuti (red, the line with intermediate shading) within populations (low heterozygosity 
when the lines show high values), and for the variance of FST between populations (green, 
the lightest line). Signatures of “new” or recent selection for CUL5 and TRIM5 in the 
Biaka are indicated by the overlapping peaks for Biaka heterozygosity and for variance of 
FST (Oleksyk et al. 2008). The positions of the genes in their respective chromosomes are 
shown in the plots. 
 
 
A. 
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Figure 3.2 (cont.) 
 
 
B. 
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Figure 3.3. Length of genomic regions under putative selection, with number of 
genes and SNPs indicated. The x-axis indicates the length in kb of regions displaying 
signatures of new or old selection in Biaka-Mbuti comparisons. The y-axis shows the 
number of SNPs present within the regions showing signatures of selection. The values 
plotted within parentheses indicate the number of genes present within each genomic 
region that displayed a signature of selection. The region under putative selection around 
CUL5 is one of the longest present in the genome, which may signal a stronger degree or 
a more recent occurrence of selection (Oleksyk et al. 2010). The number of SNPs present 
in the regions around CUL5, TRIM5 and PARD3B appear to be proportionate to the 
lengths of the regions in kb, suggesting that SNP coverage in the regions was not 
inadequate or disproportionate.  
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Table 3.1. ARGs and HDFs under potential selection in the Biaka. HDFs and ARGs 
that overlap with genomic regions found under putative selection in the current selection 
scan are sorted by the type of selection (recent in Biaka, recent in both Biaka and Mbuti, 
recent in Mbuti, or Old in Biaka and Mbuti) then ranked by the strength of selection 
measured by the product of the λ values that were used to assign the type of selection (as 
noted in methods). ARGs are in boldface. 
 
Gene Position Rank Type of Selection 
HLA-DOB 6:32874832-32906709 1 Recent in Biaka 
ATM 11:107122467-107851313 2 Recent in Biaka 
CUL5 11:107122467-107851313 2 Recent in Biaka 
FGD6 12:93915516-93996220 4 Recent in Biaka 
KPNA3 13:48904591-49229993 5 Recent in Biaka 
SESTD1 2:179590507-179848028 6 Recent in Biaka 
CHST10 2:100307191-100387056 6 Recent in Biaka 
PTPRB 12:69270162-69270286 8 Recent in Biaka 
TRIM22 11:5712786-5712786 9 Recent in Biaka 
TRIM5 11:5712786-5712786 9 Recent in Biaka 
DOCK10 2:225501079-225511799 11 Recent in Biaka 
AGBL5 2:27113973-27201533 12 Recent in Biaka 
CGREF1 2:27113973-27201533 12 Recent in Biaka 
DHX33 17:5292515-5307671 14 Recent in Biaka 
CHST9 18:22941322-23017276 15 Recent in Biaka 
TMEM163 2:135048825-135151858 16 Recent in Biaka 
ATG16L2 11:72131498-72483251 1 Recent in Biaka & Mbuti 
LAMC1 1:181319208-181444077 2 Recent in Biaka & Mbuti 
LAMC2 1:181319208-181444077 2 Recent in Biaka & Mbuti 
GPX5 6:28541114-28808331 4 Recent in Biaka & Mbuti 
GPX6 6:28541114-28808331 4 Recent in Biaka & Mbuti 
IL2 4:123320561-123721113 6 Recent in Biaka & Mbuti 
ITGAX 16:31273517-31535883 7 Recent in Biaka & Mbuti 
SNRPD1 19:50748340-50902205 1 Old in Biaka & Mbuti 
SNRPD2 19:50748340-50902205 1 Old in Biaka & Mbuti 
BRCA1 17:38465179-38497526 3 Old in Biaka & Mbuti 
POLR2J 7:101695725-102411428 4 Old in Biaka & Mbuti 
COG4 16:68486638-69167724 5 Old in Biaka & Mbuti 
ST3GAL2 16:68486638-69167724 5 Old in Biaka & Mbuti 
KCNMB2 3:179681525-179743880 7 Old in Biaka & Mbuti 
HMGCR 5:74482560-74844173 8 Old in Biaka & Mbuti 
72 
 
Table 3.1 (cont.) 
 
Gene Position Rank Type of Selection 
PDE4B 1:66387855-66456040 9 Old in Biaka & Mbuti 
EGF 4:111029826-111105755 10 Old in Biaka & Mbuti 
FBXO18 10:5984449-6002641 11 Old in Biaka & Mbuti 
SLC1A2 11:35349177-35384951 12 Old in Biaka & Mbuti 
RNF10 12:119491112-119570267 13 Old in Biaka & Mbuti 
PLCB1 20:8531414-8555393 14 Old in Biaka & Mbuti 
IL8 4:74807862-74943784 15 Old in Biaka & Mbuti 
TAT 16:70148170-70227125 16 Old in Biaka & Mbuti 
NCOR2 12:123549569-123549878 17 Old in Biaka & Mbuti 
CLOCK 4:56018354-56033550 18 Old in Biaka & Mbuti 
OPRM1 6:154403712-154456266 19 Old in Biaka & Mbuti 
PDE3A 12:20525183-20534841 20 Old in Biaka & Mbuti 
COPB1 11:14361401-14560124 21 Old in Biaka & Mbuti 
PSMA1 11:14361401-14560124 21 Old in Biaka & Mbuti 
CLNS1A 11:76670312-77272002 21 Old in Biaka & Mbuti 
PAK1 11:76670312-77272002 21 Old in Biaka & Mbuti 
PSMB2 1:35743595-35940043 25 Old in Biaka & Mbuti 
KCNMA1 10:78894205-78905202 26 Old in Biaka & Mbuti 
RPL5 1:92738557-93076039 27 Old in Biaka & Mbuti 
GABRP 5:170173072-170173072 28 Old in Biaka & Mbuti 
PSMD13 11:227087-232112 29 Old in Biaka & Mbuti 
VAV3 1:107901413-107916668 30 Old in Biaka & Mbuti 
ITGB1 10:33228108-33282407 31 Old in Biaka & Mbuti 
PARD3B 2:205683626-205683626 32 Old in Biaka & Mbuti 
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Table 3.2. ARGs and HDFs under potential selection in the Biaka. Two studies had 
examined Biaka genomes using alternative methods for identifying signatures of 
selection, described in Chapter 2 (Lopez Herraez et al. 2009; Pickrell et al. 2009). We 
examined their results for overlap between genomic regions under selection and the 
genomic locations of ARGs and HDFs. (a) top 1% of iHS signals in Biaka using a 200 kb 
sliding window using the integrated haplotype score (iHS) method. (b) top 10 iHS signals 
in Biaka using a 100 kb sliding window using the iHS method. XP-EHH (a) top 1% of 
XP-EHH signals in Biaka using a 200kb sliding window using the cross-population 
extended haplotype homozygosity (XP-EHH) method. XP-EHH (b) top 10 XP-EHH 
signals using a 200 kb sliding window moved at intervals of 100 kb. The regions under 
putative selection using the iHS and XP-EHH methods are from tables from Pickrell et al. 
(2009). The last set shown was determined from regions that scored in the top 1% when 
the Biaka were compared against average values for sub-Saharan African populations 
using the lnRsb methodology, which is similar to XP-EHH (Lopez Herraez et al. 2009). 
 
Gene Position Rank Type of Selection 
EPAS1 2:46400000-46600000 52 iHS (a) 
FUT8 14:64800000-65000000 83 iHS (a) 
ITGA6 2:173000000-173200000 25 iHS (a) 
KAT2B 3:20000000-20200000 42 iHS (a) 
MAN2A1 5:109000000-109200000 4 iHS (a) 
MAP2 2:209800000-210000000 67 iHS (a) 
PAK1 11:76600000-76800000 40 iHS (a) 
POMC 2:25200000-25400000 86 iHS (a) 
SLC4A7 3:27200000-27400000 29 iHS (a) 
SOD2 6:159800000-160200000 63 iHS (a) 
ZAP70 2:97600000-97800000 3 iHS (a) 
PIK3CG 7:106200000-106300000 5 iHS (b) 
TNFSF13B 13:107700000-107800000 9 iHS (b) 
ACE 17:58800000-59000000 31 XP-EHH (a) 
AP2S1 19:52000000-52400000 10 XP-EHH (a) 
BSG 19:400000-600000 123 XP-EHH (a) 
CAMK1D 10:12400000-12600000 58 XP-EHH (a) 
CDK5R1 17:27800000-28000000 80 XP-EHH (a) 
CEL 9:134800000-135000000 44 XP-EHH (a) 
CPN2 3:195400000-195600000 53 XP-EHH (a) 
DICER1 14:94600000-94800000 41 XP-EHH (a) 
EEF1A1 9:134800000-135000000 44 XP-EHH (a) 
FEN1 11:61200000-61400000 52 XP-EHH (a) 
FPR1 19:56800000-57000000 42 XP-EHH (a) 
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Table 3.2 (cont.) 
 
Gene Position Rank Type of Selection 
FPR2 19:56800000-57000000 42 XP-EHH (a) 
GPX4 19:1000000-1200000 95 XP-EHH (a) 
GTF2E1 3:121800000-122000000 56 XP-EHH (a) 
GTF3C5 9:134800000-135000000 44 XP-EHH (a) 
IRF7 11:600000-800000 77 XP-EHH (a) 
ITGAM 16:31200000-31600000 75 XP-EHH (a) 
ITGAX 16:31200000-31600000 75 XP-EHH (a) 
LAMC3 9:132800000-133000000 54 XP-EHH (a) 
LMNB1 5:126200000-126400000 112 XP-EHH (a) 
LRP1 12:55800000-56000000 109 XP-EHH (a) 
MME 3:156200000-156400000 61 XP-EHH (a) 
NCKAP1 2:183400000-183600000 69 XP-EHH (a) 
NFKB2 10:104000000-104200000 49 XP-EHH (a) 
NTN1 17:9000000-9200000 88 XP-EHH (a) 
NUP214 9:132800000-133000000 54 XP-EHH (a) 
PIK3CG 7:106200000-106400000 8 XP-EHH (a) 
POLR2E 19:1000000-1200000 95 XP-EHH (a) 
PRKCZ 1:1800000-2200000 67 XP-EHH (a) 
PSMD11 17:27800000-28000000 80 XP-EHH (a) 
RAB28 4:13000000-13200000 90 XP-EHH (a) 
SLC7A5 16:86400000-86600000 7 XP-EHH (a) 
SPN 11:600000-800000 77 XP-EHH (a) 
SPTBN4 19:45600000-45800000 59 XP-EHH (a) 
STAT6 12:55800000-56000000 109 XP-EHH (a) 
TATDN1 8:125400000-125600000 35 XP-EHH (a) 
TIAM2 6:155000000-155200000 115 XP-EHH (a) 
TMTC1 12:29800000-30000000 91 XP-EHH (a) 
TNFSF13B 13:107600000-107800000 14 XP-EHH (a) 
TOM1 22:34000000-34200000 66 XP-EHH (a) 
WT1 11:32400000-32600000 28 XP-EHH (a) 
PIK3CG 7:106100000-106400000 1 XP-EHH (b) 
SLC7A5 16:86300000-86600000 10 XP-EHH (b) 
TSG101 11:18500000-18800000 8 XP-EHH (b) 
VPS53 17:400000-900000 3 XP-EHH (b) 
CYP46A1 14:99085798-99455094 14 lnRSB 
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Table 3.2 (cont.) 
 
Gene Position Rank Type of Selection 
FABP1 2:88148061-88676466 23 lnRSB 
MYH11 16:15438209-15913069 3 lnRSB 
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Table 3.3. List of all ARGs and HDFs found in regions with signatures of selection 
for all pairwise comparisons. The lists of ARGs and HDFs, including the NIH listing of 
host genes that may interact with HIV-1, were matched against each of the genomic 
regions displaying signatures of selection, as determined using the method of Oleksyk 
(2008). Each adjacent shaded pair of populations listed along the top was compared. 
Within each comparison, ARGs and HDFs in regions stronger signatures of selection are 
listed first. Genes listed in bold are ARGs (and may also be HDFs); otherwise, the genes 
are HDFs but not ARGs. 
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Gene Name 
6:32874832-32906709 7  HLA-DOB 
11:107122467-107851313 10  ATM 
11:107122467-107851313 10  CUL5 
11:72131498-72483251 13  13  ATG16L2 
12:93915516-93996220 16  FGD6 
6:28541114-28808331 19  19  GPX5 
6:28541114-28808331 19  19  GPX6 
13:48904591-49229993 26  KPNA3 
4:123320561-123721113 30  30  IL2 
6:32904663-33063954 35  HLA-DMA 
6:32904663-33063954 35  HLA-DMB 
6:32904663-33063954 35  PSMB8 
6:32904663-33063954 35  PSMB9 
6:32904663-33063954 35  TAP1 
16:31273517-31535883 50  50  ITGAX 
2:179590507-179848028 62  SESTD1 
10:76140605-76493170 66  MYST4 
2:100249892-100387056 91  CHST10 
12:69270162-69270286 100  PTPRB 
6:33739674-33739674 107  ITPR3 
11:124907656-125122820 114  CHEK1 
11:124907656-125122820 114  STT3A 
17:40030438-40411105 122  GFAP 
7:31754514-31835138 124  PDE1C 
7:31754514-31835138 125  PDE1C 
11:5712786-5712786 133  TRIM22 
11:5712786-5712786 133  TRIM5 
2:225501079-225511799 134  DOCK10 
2:27113298-27201533 143  AGBL5 
2:27113298-27201533 143  CGREF1 
17:5292515-5307671 146  DHX33 
18:22941322-23017276 148  CHST9 
7:31754514-31835138 160  PDE1C 
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Table 3.3 (cont.) 
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2:135048825-135151858 161  TMEM163 
16:31112063-31466721 178  ITGAM 
16:31112063-31466721 178  ITGAX 
7:31820766-31835138 188 188 PDE1C 
19:50748340-50913566 196 196 SNRPD1 
19:50748340-50913566 196 196 SNRPD2 
11:5712786-5788767 216  TRIM22 
11:5712786-5788767 216  TRIM5 
2:37256459-37538245 220  PRKD3 
2:37270556-37538245 221  PRKD3 
11:73023689-73259191 224 224 RAB6A 
11:73023689-73259191 224 224 RAB6C 
17:38465179-38497526 228 228 BRCA1 
9:21285828-21446776 232  IFNA1 
9:21285828-21446776 232  IFNA2 
13:69576559-69699626 233 233 KLHL1 
7:101695725-102411428 272 272 POLR2J 
10:74384183-75328587 292  PLA2G12B 
10:74384183-75328587 292  PPP3CB 
16:68486638-69167724 303 303 COG4 
16:68486638-69167724 303 303 ST3GAL2 
3:179666399-179743880 310 310 KCNMB2 
5:74482560-74844173 311 311 HMGCR 
4:111029826-111105755 330 330 EGF 
12:55796928-56134906 335  LRP1 
12:55796928-56134906 335  STAT6 
10:5984449-6002641 336 336 FBXO18 
7:101695725-102303980 360 360 POLR2J 
9:2003580-2085771 367  SMARCA2 
3:135120582-135218551 369  SLCO2A1 
11:35349177-35384951 371 371 SLC1A2 
12:119491112-119570267 377 377 RNF10 
6:155217169-155217169 383  TIAM2 
20:8531414-8555393 387 387 PLCB1 
4:74807862-74943784 393 393 IL8 
16:70148170-70227125 403 403 TAT 
12:123549569-123549878 414 414 NCOR2 
4:56018354-56033550 430 430 CLOCK 
2:178598575-178598775 442 442 PDE11A 
6:154403712-154456266 443 443 OPRM1 
20:47206669-47259294 446  STAU1 
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Table 3.3 (cont.) 
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12:20525183-20534841 477 477 PDE3A 
11:14361401-14560124 478 478 COPB1 
11:14361401-14560124 478 478 PSMA1 
12:55618203-56134906 479  GPR182 
12:55618203-56134906 479  LRP1 
12:55618203-56134906 479  STAT6 
3:46904550-46953927 489 489 PTHR1 
7:101695725-102411428 491 491 POLR2J 
11:76670312-77272002 499 499 CLNS1A 
11:76670312-77272002 499 499 PAK1 
10:78894205-78905202 519 519 KCNMA1 
6:26298726-26375779 532 532 HIST1H2A
D 
6:26298726-26375779 532 532 HIST1H2A
E 
6:26298726-26375779 532 532 HIST1H2B
F 
6:26298726-26375779 532 532 HIST1H2B
G 
6:26298726-26375779 532 532 HIST1H2B
H 
6:26298726-26375779 532 532 HIST1H3A 
6:26298726-26375779 532 532 HIST1H3B 
6:26298726-26375779 532 532 HIST1H3C 
6:26298726-26375779 532 532 HIST1H3D 
6:26298726-26375779 532 532 HIST1H3E 
6:26298726-26375779 532 532 HIST1H3F 
6:26298726-26375779 532 532 HIST1H3G 
6:26298726-26375779 532 532 HIST1H3H 
6:26298726-26375779 532 532 HIST1H3I 
6:26298726-26375779 532 532 HIST1H3J 
6:26298726-26375779 532 532 HIST1H4A 
6:26298726-26375779 532 532 HIST1H4B 
6:26298726-26375779 532 532 HIST1H4C 
6:26298726-26375779 532 532 HIST1H4D 
6:26298726-26375779 532 532 HIST1H4E 
6:26298726-26375779 532 532 HIST1H4F 
6:26298726-26375779 532 532 HIST1H4G 
6:26298726-26375779 532 532 HIST1H4H 
6:26298726-26375779 532 532 HIST1H4I 
6:26298726-26375779 532 532 HIST1H4J 
6:26298726-26375779 532 532 HIST1H4K 
6:26298726-26375779 532 532 HIST1H4L 
6:26298726-26375779 532 532 HIST2H4A 
6:26298726-26375779 532 532 HIST4H4 
5:170173072-170173072 578 578 GABRP 
12:8648058-8905984 584  AICDA 
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Gene Name 
11:227087-232112 587 587 PSMD13 
12:84127662-84147479 600 600 LRRIQ1 
16:46053294-46215694 606 606 PHKB 
16:46053294-46215694 607 607 PHKB 
10:33228108-33282407 613 613 ITGB1 
17:27662317-27799874 616 616 PSMD11 
5:59277491-59463499 637 637 PDE4D 
2:205683626-205683626 638 638 PARD3B 
12:119491112-119570267 647 647 RNF10 
22:27886739-28177722 671  AP1B1 
12:8648058-8904596 677  AICDA 
16:31273517-34637302 1  1  ITGAX 
16:31273517-34637302 1  1  ZNF720 
10:96023756-96427689 13  13  PLCE1 
3:128745447-128922832 15  ABTB1 
19:43477158-43811334 17  PSMD8 
5:167783746-167985714 33  33  PANK3 
14:73236430-73483173 46  46  DNAL1 
21:46610952-46841625 53  PCNT 
2:9611326-9733217 62  YWHAQ 
17:24859695-25068227 65  65  TAOK1 
5:151032339-151270918 97  ATOX1 
16:69996550-70205800 103 103 CHST4 
16:69996550-70205800 103 103 TAT 
12:93905833-93995461 105  105  FGD6 
11:5810765-5922991 111  111  TRIM5 
6:32249861-32273561 125 125 RNF5 
20:8247380-8273418 138  PLCB1 
22:33994327-34154824 142  TOM1 
2:70558910-70564691 146  TGFA 
11:73140406-73259556 168 168 RAB6A 
11:73140406-73259556 168 168 RAB6C 
4:74843755-74969011 186 186 CXCL1 
2:178576047-178708537 210 210 PDE11A 
1:92717582-93125257 214 214 RPL5 
14:64992878-65015804 217 217 FUT8 
3:128745447-128922832 230  230  ABTB1 
16:23435624-23619949 232  ERN2 
16:23435624-23619949 232  PLK1 
10:6530227-6544132 250 250 PRKCQ 
14:23800302-23840209 259 259 TGM1 
5:118551008-118598071 278 278 DMXL1 
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Gene Name 
17:70822168-71019461 280 280 GRB2 
11:65943458-66316599 288 288 SPTBN2 
12:26670546-26670546 292  ITPR2 
5:32144879-32171356 294 294 GOLPH3 
19:48635339-48705100 300 300 ETHE1 
19:14513278-14538312 305  GPSN2 
19:14513278-14538312 305  NDUFB7 
1:100948239-100988583 316  VCAM1 
1:107915388-107957883 336 336 VAV3 
13:107717404-107741035 343 343 TNFSF13B 
10:5984449-6000636 349 349 FBXO18 
12:38637192-38779683 372 372 SLC2A13 
8:11409494-11409494 377 377 BLK 
5:59269104-59308563 379  PDE4D 
11:11556970-11587617 383 383 GALNTL4 
8:134325741-134332892 395 395 NDRG1 
6:12194812-12194812 400 400 HIVEP1 
17:544990-565912 406 406 VPS53 
15:53952815-54096833 408 408 NEDD4 
7:31826228-31859481 415 415 PDE1C 
10:12478789-12486578 416 416 CAMK1D 
12:119324905-119553584 418 418 RNF10 
5:179857956-179876561 423 423 CCR4 
3:42766127-42841126 426 426 CCBP2 
11:14441221-14468636 443 443 COPB1 
7:102347004-102794835 444 444 PSMC2 
7:7647656-7648700 447 447 RPA3 
19:2049015-2060019 449  AP3D1 
22:30678239-30701492 477 477 YWHAH 
6:155054005-155224256 480  TIAM2 
11:226871-233268 484 484 PSMD13 
11:226871-233268 485 485 PSMD13 
2:37164843-37207653 489 489 EIF2AK2 
12:15706025-15707557 495  EPS8 
18:65551119-65551119 508 508 DOK6 
6:154383069-154420845 574 574 OPRM1 
15:56783117-56784541 625 625 ADAM10 
1:180377811-180826133 11  RNASEL 
10:74363276-76043910 12  AP3M1 
10:74363276-76043910 12  PLA2G12B 
10:74363276-76043910 12  PLAU 
10:74363276-76043910 12  PPP3CB 
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Gene Name 
10:74363276-76043910 12  VCL 
7:100639893-100857977 20  PLOD3 
2:197241610-197585174 25  GTF3C3 
1:184890093-185136886 33  PLA2G4A 
1:184890093-185136886 33  PTGS2 
21:46655271-46676181 35  PCNT 
16:34132640-45212171 36  36  SHCBP1 
5:109016922-109136881 38  MAN2A1 
15:63548169-64159966 44  44  RAB11A 
15:63548169-64159966 44  44  SLC24A1 
18:17043299-17610456 51  SNRPD1 
15:40769632-41848175 55  MAP1A 
15:40769632-41848175 55  PDIA3 
15:40769632-41848175 55  TGM5 
15:40769632-41848175 55  TGM7 
11:47301676-47655974 70  MADD 
11:47301676-47655974 70  NDUFS3 
11:47301676-47655974 70  PSMC3 
14:72495434-72759382 72  RBM25 
16:15787511-15813631 95  MYH11 
2:95371030-96035728 97  KCNIP3 
5:43135962-43406123 116  116  HMGCS1 
2:24899594-24951148 118  ADCY3 
17:74386107-74455624 125  TIMP2 
2:225601556-225604258 142  DOCK10 
2:200877238-201013331 150  LOC26010 
8:48601566-49356903 155  PRKDC 
11:12432807-12432807 172  PARVA 
16:69988254-70205800 173 173 CHST4 
16:69988254-70205800 173 173 TAT 
11:125586613-125798247 217  ST3GAL4 
11:35079627-35206246 222  CD44 
9:2055892-2084590 225  SMARCA2 
13:37074489-37123131 236 236 TRPC4 
12:119479715-119566611 266 266 RNF10 
10:35421379-35514705 275 275 CREM 
10:5985678-6028077 287 287 FBXO18 
13:107670522-107741035 309 309 TNFSF13B 
2:171464683-171498633 313  GORASP2 
8:134564796-134581991 319 319 ST3GAL1 
3:135181039-135360260 324  SLCO2A1 
1:232618986-232669495 328  TARBP1 
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Gene Name 
7:31892341-31924539 351 351 PDE1C 
6:154403712-154456266 363 363 OPRM1 
19:12923663-12975434 395  RAD23A 
19:12923663-12975434 395  SP1 
1:21913660-22162743 396  HSPG2 
10:90718761-90718761 400 400 ACTA2 
7:93887292-93931680 420 420 COL1A2 
11:14393309-14468636 446 446 COPB1 
11:66165985-66390973 447 447 SPTBN2 
3:12638233-12643726 456  RAF1 
14:67122902-67864865 4  PIGH 
16:31318686-45318216 7  7  SHCBP1 
16:31318686-45318216 7  7  ZNF720 
16:70051598-70450999 12  AP1G1 
16:70051598-70450999 12  CHST4 
16:70051598-70450999 12  TAT 
14:30061258-30275385 17  17  SCFD1 
22:34041543-34224316 25  TOM1 
11:76874833-77408373 27  CLNS1A 
8:36758291-36894633 28  28  FKSG2 
7:31774864-31859481 30  PDE1C 
12:93928789-93995461 32  32  FGD6 
13:107634383-107767871 39  39  TNFSF13B 
19:10613968-10755922 42  42  DNM2 
19:10613968-10755922 42  42  ILF3 
10:32708723-33305561 45  45  ITGB1 
15:27693153-27833209 56  56  TJP1 
1:153675259-154530564 73  DAP3 
1:153675259-154530564 73  LMNA 
1:153675259-154530564 73  MAPBPIP 
1:153675259-154530564 73  UBQLN4 
2:95035474-96047105 75  KCNIP3 
2:183086558-183234573 80  PDE1A 
10:90737149-90792904 81  ACTA2 
10:90737149-90792904 81  FAS 
20:31912990-32247488 84  EIF2S2 
5:74654888-75024125 92  HMGCR 
1:20281961-20317060 108  PLA2G2D 
1:20281961-20317060 108  PLA2G5 
2:24617313-24982223 117  ADCY3 
2:24617313-24982223 117  NCOA1 
1:181456056-181538918 118  LAMC2 
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Gene Name 
20:29324345-29817803 124 124 BCL2L1 
20:29324345-29817803 124 124 ID1 
17:26151077-26676582 133  EVI2A 
17:26151077-26676582 134  EVI2A 
17:26151077-26676582 135  EVI2A 
6:96104083-96142637 156  MANEA 
9:74250072-74378110 166 166 TMC1 
11:9885582-10118803 170  SBF2 
1:23587252-23709352 173 173 TCEA3 
21:33709182-33848130 177 177 IFNGR2 
8:22842941-22942763 209 209 TNFRSF10
B 
10:5984449-6002641 220 220 FBXO18 
8:19857956-19869148 233  LPL 
11:11518582-11608164 238 238 GALNTL4 
1:66146592-66161685 247  PDE4B 
20:39028374-39154787 254 254 TOP1 
6:33205592-33656372 264  B3GALT4 
6:33205592-33656372 264  PHF1 
18:22940363-23004144 269  CHST9 
2:178502285-178619264 302 302 PDE11A 
7:140946965-141125269 308  SSBP1 
4:87361272-87632448 318  MAPK10 
11:226871-233268 323 323 PSMD13 
5:179857956-179876561 327 327 CCR4 
12:123553573-123568478 366 366 NCOR2 
3:179642146-179743880 371 371 KCNMB2 
4:24395603-24479151 374 374 SOD3 
17:4832680-5317182 381 381 C1QBP 
17:4832680-5317182 381 381 DHX33 
17:4832680-5317182 381 381 USP6 
17:4832680-5317182 381 381 ZNF594 
17:453788-595982 390 390 VPS53 
9:133448145-133460974 422 422 RAPGEF1 
2:134977373-134977373 423 423 TMEM163 
6:154390298-154499899 429 429 OPRM1 
8:142062878-142094332 432 432 PTK2 
6:155812700-155813731 457 457 NOX3 
2:46050436-46053488 476 476 PRKCE 
6:42041532-42042625 484 484 CCND3 
8:134327611-134334677 489 489 NDRG1 
11:18416884-18428709 490 490 LDHC 
8:56517026-56517026 497  XKR4 
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Gene Name 
7:5664105-5685079 522 522 RNF216 
7:5664105-5685079 522 522 TRIAD3 
2:200857266-200889673 546  LOC26010 
14:73236430-73236430 550 550 DNAL1 
2:205737668-205742026 551 551 PARD3B 
11:93788997-93804974 584 584 MRE11A 
8:25716309-25716309 590 590 PPP2R2A 
4:111120647-111120647 615 615 EGF 
17:61640002-61641042 619 619 APOH 
10:6547609-6547609 623 623 PRKCQ 
11:35238672-35286191 634 634 SLC1A2 
8:11408287-11408287 635 635 BLK 
10:73920978-75277174 1  PLA2G12B 
10:73920978-75277174 1  PPP3CB 
2:31595971-32348899 5  5  SPAST 
2:31595971-32348899 5  5  SRD5A2 
1:84052058-84427826 14  14  PRKACB 
1:180599754-180899210 15  RNASEL 
6:30838246-31090523 23  23  GTF2H4 
8:48175012-49699200 24  PRKDC 
16:30037994-31055049 25  ITGAL 
16:30037994-31055049 25  MAPK3 
16:30037994-31055049 25  MYST1 
16:30037994-31055049 25  ZNF688 
16:30037994-31055049 25  ZNF747 
16:30037994-31055049 25  ZNF785 
5:43186152-43406123 27  HMGCS1 
15:63548169-64126454 34  34  RAB11A 
15:63548169-64126454 34  34  SLC24A1 
15:63548169-64126454 35  35  RAB11A 
15:63548169-64126454 35  35  SLC24A1 
6:33143855-33204252 36  HLA-DPA1 
6:33143855-33204252 36  HLA-DPB1 
12:111145487-111407744 59  PTPN11 
2:94978884-96222641 65  KCNIP3 
2:94978884-96222641 65  LOC150763 
3:23902030-24094861 71  UBE2E1 
13:49040596-49184219 72  KPNA3 
12:55880161-56137449 81  81  LRP1 
20:47080475-47422312 82  STAU1 
6:90228257-90327535 88  ANKRD6 
1:232618634-232739896 89  TARBP1 
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Gene Name 
2:24725967-25165041 90  ADCY3 
2:24725967-25165041 90  NCOA1 
10:12875389-12882926 105  CAMK1D 
2:171526992-171764496 106  GORASP2 
3:170525673-170680718 112  EVI1 
14:72511945-72861024 130  RBM25 
5:74449469-74959712 131 131 HMGCR 
5:74449469-74959712 132 132 HMGCR 
11:9860202-10310293 136  SBF2 
12:84078462-84240895 145 145 ALX1 
12:84078462-84240895 145 145 LRRIQ1 
16:74131925-74131925 148  CHST5 
1:66059788-66283992 152  PDE4B 
20:29698963-29872241 166 166 BCL2L1 
20:29698963-29872241 166 166 MYLK2 
9:2063839-2084590 176  SMARCA2 
10:5984421-6042374 181 181 FBXO18 
2:37372220-37372220 186 186 PRKD3 
15:65187544-65200891 200  SMAD3 
11:76932954-77168498 209 209 CLNS1A 
10:95923791-95948321 215  PLCE1 
19:10747206-10880543 224  DNM2 
19:10747206-10880543 224  TMED1 
4:74807802-74865179 231 231 IL8 
6:154403712-154456266 243 243 OPRM1 
17:3477153-3582394 249  P2RX5 
1:116827132-116954482 250 250 CD58 
17:40344589-40382401 251 251 GFAP 
3:135213622-135213622 273  SLCO2A1 
2:182045129-182346202 282  ITGA4 
2:197199091-197423323 284  GTF3C3 
10:12347969-12486578 314 314 CAMK1D 
21:46597605-46610952 327  PCNT 
10:32896752-33276311 337 337 ITGB1 
7:81187348-81209555 353 353 HGF 
19:16439881-16462154 355  MED26 
3:133615389-133864830 365 365 CCBP2 
3:133615389-133864830 365 365 NPHP3 
19:50850483-50894012 368 368 SNRPD1 
19:50850483-50894012 368 368 SNRPD2 
4:110975660-111093375 370 370 EGF 
9:94481854-94638021 404  BICD2 
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21:42390338-42390509 408 408 UMODL1 
7:98577167-98626525 416 416 SMURF1 
12:116179703-116179703 424 424 NOS1 
1:245111315-245125328 425 425 ELYS 
8:56518052-56518052 428  XKR4 
17:23086489-23226350 458  NOS2 
8:141775502-142083719 466 466 PTK2 
11:226871-232112 477 477 PSMD13 
11:226871-232112 478 478 PSMD13 
5:43206411-44084648 2  HMGCS1 
11:72149984-72565260 3  ATG16L2 
6:32873108-32920894 4  4  HLA-DOB 
6:32873108-32920894 4  4  PSMB8 
22:34061175-34252550 6  6  TOM1 
14:67125637-67884400 7  PIGH 
1:181275819-181527282 8  8  LAMC1 
1:181275819-181527282 8  8  LAMC2 
16:31318686-45409739 9  9  SHCBP1 
16:31318686-45409739 9  9  ZNF720 
5:118303768-118636074 26  DMXL1 
7:31799992-31863766 46  PDE1C 
11:5819108-5862649 49  49  TRIM5 
2:95252161-96621255 53  53  ARID5A 
2:95252161-96621255 53  53  KCNIP3 
2:95252161-96621255 53  53  LOC150763 
4:123237584-123721113 74  IL2 
2:162428347-162907534 78  DPP4 
10:6529779-6577462 87  PRKCQ 
19:46903147-47797213 92  ARHGEF1 
19:46903147-47797213 92  LYPD4 
19:46903147-47797213 92  RABAC1 
5:59264373-59418081 93  PDE4D 
1:153675259-154009934 96  DAP3 
7:140941527-141251553 100  SSBP1 
13:47482941-47979890 112  112  MED4 
13:47482941-47979890 112  112  RB1 
7:5664105-5687974 113  RNF216 
7:5664105-5687974 113  TRIAD3 
15:56693437-56790047 138  ADAM10 
17:5336107-5390389 140 140 NLRP1 
1:117694341-117831407 149  MAN1A2 
5:74656133-74984799 155 155 HMGCR 
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Gene Name 
11:108044814-108432036 166  DDX10 
14:30080368-30167096 168 168 SCFD1 
5:179200555-179254263 177 177 LOC51149 
22:30671957-30679063 222 222 YWHAH 
10:74564381-75086795 227  PPP3CB 
3:27420975-27565426 236 236 SLC4A7 
16:85993964-86143037 240 240 MAP1LC3B 
9:133438117-133482300 241 241 RAPGEF1 
10:12475385-12486578 260 260 CAMK1D 
10:17785130-17931828 261 261 MRC1 
4:74825239-74977303 280 280 CXCL1 
4:74825239-74977303 280 280 IL8 
3:42830769-42841126 281 281 CCBP2 
8:56520828-56529289 285  XKR4 
10:35399625-35566580 287  CREM 
2:178476929-178541360 288 288 PDE11A 
5:131980304-132071250 292 292 IL13 
5:131980304-132071250 292 292 IL4 
5:131980304-132071250 292 292 KIF3A 
3:179769634-179775047 296 296 KCNMB2 
4:24396002-24511681 299 299 SOD3 
8:22853665-23075599 315 315 TNFRSF10
B 
8:22853665-23075599 315 315 TNFRSF10
C 
8:22853665-23075599 315 315 TNFRSF10
D 
5:167913103-168026100 316 316 PANK3 
11:18092622-18607834 383 383 GTF2H1 
11:18092622-18607834 383 383 LDHA 
11:18092622-18607834 383 383 LDHC 
11:18092622-18607834 383 383 TSG101 
11:128366132-128772691 389  RICS 
7:24826487-24835388 421 421 OSBPL3 
10:33247503-33289139 425 425 ITGB1 
15:82488383-83142863 434 434 GOLGA9P 
17:63980785-64144160 436 436 PRKAR1A 
11:35772348-35827583 464 464 TRIM44 
8:142072236-142082043 466 466 PTK2 
18:72273927-72311963 481  ZNF516 
8:134322120-134332892 486 486 NDRG1 
4:111105192-111173358 513 513 EGF 
6:154365602-154499899 524 524 OPRM1 
17:524930-559358 530 530 VPS53 
13:40542722-40542722 555 555 WBP4 
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17:38467522-38487996 557 557 BRCA1 
17:45258145-45258850 594 594 MYST2 
2:119461597-119465947 603 603 MARCO 
11:32367676-32367676 604 604 WT1 
5:43038580-44133952 1  1  HMGCS1 
10:73895227-75323806 2  2  PLA2G12B 
10:73895227-75323806 2  2  PPP3CB 
1:180579380-180867474 7  7  RNASEL 
6:30843208-31040511 12  12  GTF2H4 
15:63615394-64054161 17  17  RAB11A 
15:63615394-64054161 17  17  SLC24A1 
8:48554848-49708138 18  18  PRKDC 
19:46938403-47702683 21  ARHGEF1 
19:46938403-47702683 21  LYPD4 
19:46938403-47702683 21  RABAC1 
15:40758191-41589316 22  22  TGM5 
15:40758191-41589316 22  22  TGM7 
2:95003231-96407530 23  KCNIP3 
2:95003231-96407530 23  LOC150763 
18:65296049-65329660 36  DOK6 
10:103023116-103998270 47  47  BTRC 
12:111327746-111406912 56  56  PTPN11 
3:4431185-4535263 65  ITPR1 
17:38465179-39061480 70  70  BRCA1 
1:84209899-84490571 79  79  PRKACB 
18:72218128-72278514 94  94  ZNF516 
8:56460663-56514735 99  XKR4 
1:32562633-32835141 102  HDAC1 
6:34911345-35109114 111  TAF11 
19:10589030-10936706 113  DNM2 
19:10589030-10936706 113  ILF3 
19:10589030-10936706 113  SMARCA4 
19:10589030-10936706 113  TMED1 
2:208741802-208923693 123 123 IDH1 
10:35381307-35594060 152 152 CREM 
16:34375290-46044318 159  DNAJA2 
16:34375290-46044318 159  GPT2 
16:34375290-46044318 159  SHCBP1 
11:35173476-35187181 161 161 CD44 
17:40283491-40359010 180 180 GFAP 
11:72131498-72587520 210  ATG16L2 
8:54319624-54325439 229 229 OPRK1 
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Gene Name 
11:124931533-125076151 239  CHEK1 
11:124931533-125076151 239  STT3A 
11:124931533-125076151 240  CHEK1 
11:124931533-125076151 240  STT3A 
16:4344621-4600248 242  HMOX2 
7:6083678-6398215 246 246 RAC1 
12:115921244-116169521 248 248 FBXO21 
12:115921244-116169521 248 248 NOS1 
2:24992491-24992491 249  ADCY3 
3:170412705-170455496 251  EVI1 
14:64039095-64186303 253 253 HSPA2 
1:209486942-209686326 263 263 TRAF5 
4:111007442-111056736 282 282 EGF 
5:59153037-59153037 288  PDE4D 
13:49040596-49214353 298  KPNA3 
17:55035262-55075277 306 306 CLTC 
5:74653942-74823066 308 308 HMGCR 
11:66557823-66582736 312 312 RHOD 
4:56018354-56018354 335 335 CLOCK 
9:21314554-21373734 340 340 IFNA1 
4:74647772-74969011 366  CXCL1 
4:74647772-74969011 366  IL8 
6:154403712-154456266 368 368 OPRM1 
16:74131925-74131925 373  CHST5 
11:110927427-111178749 446 446 PPP2R1B 
1:43598899-43700464 464 464 CDC20 
1:43598899-43700464 464 464 MED8 
6:42000787-42033282 466 466 CCND3 
6:32390011-32685358 2  2  HLA-DRA 
6:32390011-32685358 2  2  HLA-DRB1 
6:32390011-32685358 2  2  HLA-DRB5 
11:43694006-43862060 10  10  DEPC-1 
14:63984290-64231183 26  26  HSPA2 
1:86812533-87250374 28  CLCA3 
1:86812533-87250374 28  CLCA4 
2:197340617-197738512 32  GTF3C3 
19:43465362-43721041 37  37  PSMD8 
19:47009491-47889875 63  ARHGEF1 
19:47009491-47889875 63  LYPD4 
19:47009491-47889875 63  RABAC1 
17:74251445-74429726 70  TIMP2 
9:131608321-131676024 75  USP20 
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7:5674025-5894482 77  RNF216 
7:5674025-5894482 77  TRIAD3 
3:27343925-27443588 89 89 SLC4A7 
19:10609820-10852827 107  DNM2 
19:10609820-10852827 107  ILF3 
19:10609820-10852827 107  TMED1 
19:17941991-18029674 122  KCNN1 
2:95335149-96047105 125 125 KCNIP3 
16:15777026-15887748 129  MYH11 
15:63592039-63929051 139 139 SLC24A1 
16:31567928-45096893 143 143 ZNF720 
3:51171463-51543177 144 144 VPRBP 
13:45002664-45128861 157  COG3 
13:45002664-45128861 157  FLJ32682 
10:69330500-69490915 162 162 SIRT1 
17:29664322-29671857 171 171 CCL8 
12:38700898-38789012 181 181 SLC2A13 
8:86443150-86609494 191  CA2 
4:74849070-74969011 192 192 CXCL1 
22:30679063-30802930 204 204 SLC5A1 
22:30679063-30802930 204 204 YWHAH 
22:28207625-28402759 208  NF2 
9:122618785-122645922 213 213 PSMD5 
12:6317783-6324558 216  TNFRSF1A 
2:71321479-71544308 249  DYSF 
1:22246211-22281114 252 252 CDC42 
16:3658493-3731262 253 253 CREBBP 
11:5880637-5889688 257 257 TRIM5 
11:128348083-128587624 258  RICS 
17:520795-544990 260 260 VPS53 
12:84080919-84251286 264 264 ALX1 
12:84080919-84251286 264 264 LRRIQ1 
12:19499661-19518231 268 268 AEBP2 
14:30154839-30188718 298  SCFD1 
13:107651324-107754759 318 318 TNFSF13B 
17:64004331-64147713 321 321 PRKAR1A 
17:5365801-5429236 338 338 NLRP1 
12:115927285-116204568 341 341 FBXO21 
12:115927285-116204568 341 341 NOS1 
10:1402163-1405366 348 348 ADARB2 
9:96364019-96370774 351  FBP2 
18:65620255-65624033 365  DOK6 
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21:45141068-45141068 375  ITGB2 
8:23000640-23018498 376 376 TNFRSF10
C 3:42780585-42845399 381 381 CCBP2 
8:56521381-56521381 382 382 XKR4 
13:40505174-40623478 398 398 WBP4 
5:112356166-112371443 418 418 DCP2 
6:17711179-17862940 433 433 NUP153 
16:16143182-16159883 448 448 ABCC1 
3:170407306-170445294 466 466 EVI1 
9:138443022-138455027 479 479 INPP5E 
16:20695271-20796113 511 511 EXOD1 
7:151150061-151151192 531  PRKAG2 
15:82497201-82976754 535 535 GOLGA9P 
2:24927590-24927590 555 555 ADCY3 
6:154357003-154470229 558 558 OPRM1 
10:35433675-35472411 563 563 CREM 
19:57384108-57396773 580 580 PPP2R1A 
5:59149058-59149058 588 588 PDE4D 
5:491564-869095 7  TPPP 
17:56987655-57581786 9  NACAL 
16:69500701-70183381 10  CHST4 
16:69500701-70183381 10  TAT 
12:116034122-116232070 13  13  FBXO21 
12:116034122-116232070 13  13  NOS1 
17:70956242-71592038 14  14  H3F3A 
17:70956242-71592038 14  14  H3F3B 
17:70956242-71592038 14  14  HCNGP 
17:70956242-71592038 14  14  ITGB4 
3:128735380-128878910 21  21  ABTB1 
9:94012305-94655970 31  31  BICD2 
16:15420076-15823359 32  MYH11 
5:179827466-179935691 34  34  CCR4 
6:31604894-31968316 37  BAT3 
6:31604894-31968316 37  CSNK2B 
6:31604894-31968316 37  HSPA1A 
6:31604894-31968316 37  HSPA1B 
6:31604894-31968316 37  LTA 
6:31604894-31968316 37  NEU1 
6:31604894-31968316 37  TNF 
3:51388534-51630896 49 49 VPRBP 
2:95301689-96159671 56 56 KCNIP3 
2:95301689-96159671 56 56 LOC150763 
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Gene Name 
2:24870861-24969960 85 85 ADCY3 
9:96383441-96468981 99  FBP1 
9:96383441-96468981 99  FBP2 
14:30098936-30278882 112  SCFD1 
13:18646709-18656911 117  TUBA3C 
15:96991004-97030008 118  IGF1R 
20:31966721-32337108 120  EIF2S2 
2:157164786-157164786 127  GPD2 
11:11510219-11664195 132 132 GALNTL4 
1:100255128-100444648 138  SLC35A3 
12:84086307-84162220 139 139 LRRIQ1 
11:9863613-10012881 140  SBF2 
19:10691281-10822273 147 147 DNM2 
19:10691281-10822273 147 147 TMED1 
7:65175866-65358874 170 170 TPST1 
17:520795-579938 201 201 VPS53 
1:66045878-66183129 214  PDE4B 
9:122626558-122643290 217 217 PSMD5 
6:155808379-155866536 220 220 NOX3 
17:8966802-9000751 223 223 NTN1 
7:102415551-102822491 224 224 PSMC2 
20:43187328-43359987 237 237 SLPI 
2:178483634-178598775 243 243 PDE11A 
8:66802644-66984584 250  PDE7A 
17:74396712-74441474 252  TIMP2 
3:42766127-42845399 259 259 CCBP2 
17:64004331-64151502 281 281 PRKAR1A 
6:12184157-12197891 282 282 HIVEP1 
6:26105437-26139847 286 286 HIST1H3A 
6:26105437-26139847 286 286 HIST1H3B 
6:26105437-26139847 286 286 HIST1H3C 
6:26105437-26139847 286 286 HIST1H3D 
6:26105437-26139847 286 286 HIST1H3E 
6:26105437-26139847 286 286 HIST1H3F 
6:26105437-26139847 286 286 HIST1H3G 
6:26105437-26139847 286 286 HIST1H3H 
6:26105437-26139847 286 286 HIST1H3I 
6:26105437-26139847 286 286 HIST1H3J 
6:26105437-26139847 286 286 HIST1H4A 
6:26105437-26139847 286 286 HIST1H4B 
6:26105437-26139847 286 286 HIST1H4C 
6:26105437-26139847 286 286 HIST1H4D 
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Gene Name 
6:26105437-26139847 286 286 HIST1H4E 
6:26105437-26139847 286 286 HIST1H4F 
6:26105437-26139847 286 286 HIST1H4H 
6:26105437-26139847 286 286 HIST1H4I 
6:26105437-26139847 286 286 HIST1H4J 
6:26105437-26139847 286 286 HIST1H4K 
6:26105437-26139847 286 286 HIST1H4L 
6:26105437-26139847 286 286 HIST2H4A 
6:26105437-26139847 286 286 HIST4H4 
2:197340617-197533147 288 288 GTF3C3 
13:107641512-107787699 299 299 TNFSF13B 
11:12330374-12387302 303 303 PARVA 
8:134322616-134329999 341 341 NDRG1 
2:70558910-70564691 393  TGFA 
7:106555592-106734359 406 406 PRKAR2B 
1:159193918-159411629 432 432 B4GALT3 
15:63480609-63908644 434 434 SLC24A1 
21:31888035-31978730 467 467 SOD1 
4:87545748-87724510 475 475 MAPK10 
20:52109454-52115612 492 492 BCAS1 
8:56520828-56520828 494 494 XKR4 
10:88291311-88607372 503 503 OPN4 
13:40525677-40621779 504 504 WBP4 
11:214393-226871 507 507 PSMD13 
11:214393-226871 508 508 PSMD13 
6:154402201-154429999 519 519 OPRM1 
1:40520506-40520506 540  ZMPSTE24 
2:68244591-68366991 574 574 PPP3R1 
10:1718840-1729576 588 588 ADARB2 
1:166963238-167011760 592 592 DPT 
2:230748877-230767198 593  SP110 
6:152328988-152334365 599  ESR1 
17:31064899-31078012 609 609 AP2B1 
4:74866956-74956794 613 613 CXCL1 
14:23800883-23863602 633 633 ADCY4 
14:23800883-23863602 633 633 TGM1 
11:66084671-66272625 670 670 SPTBN2 
1:182269497-182290152 691 691 GLT25D2 
7:37330503-37331191 692 692 ELMO1 
6:167412542-167412542 695 695 CCR6 
6:32487714-32766602 4  HLA-DQA1 
6:32487714-32766602 4  HLA-DQB1 
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Gene Name 
6:32487714-32766602 4  HLA-DRA 
6:32487714-32766602 4  HLA-DRB1 
6:32487714-32766602 4  HLA-DRB5 
17:44183411-44439710 8  UBE2Z 
11:128312133-128619142 11  RICS 
3:170577457-170694461 17  17  EVI1 
5:43272945-44113129 22  HMGCS1 
5:59807480-59975475 24  24  PDE4D 
13:107712281-107754318 26  26  TNFSF13B 
11:63718728-63805488 29  BAD 
11:63718728-63805488 29  PLCB3 
11:63718728-63805488 29  STIP1 
11:63718728-63805488 29  TRPT1 
12:85235742-85966611 32  MGAT4C 
21:45136241-45141068 42  ITGB2 
11:3656040-3713262 75  NUP98 
2:95092780-96173058 81 81 KCNIP3 
2:95092780-96173058 81 81 LOC150763 
2:197969715-198351666 83  HSPD1 
2:197969715-198351666 83  HSPE1 
2:197969715-198351666 83  SF3B1 
4:22315249-22320167 85  GBA3 
17:3474412-3579585 89 89 P2RX5 
15:97046853-97046853 100  IGF1R 
14:23727066-23821574 105  105  CHMP4A 
14:23727066-23821574 105  105  TGM1 
6:170602082-170656551 106  PSMB1 
5:74503175-74996114 107 107 HMGCR 
1:66049573-66268696 115  PDE4B 
8:27268193-27279599 116  PTK2B 
14:64039095-64224588 124 124 HSPA2 
3:182133656-182208750 126 126 FXR1 
2:24917697-24956612 136 136 ADCY3 
9:130904921-131021918 148  PPP2R4 
20:43288091-43353860 159  SLPI 
14:67130128-67307877 163 163 PIGH 
14:38605311-38691012 167  SIP1 
12:13614394-13614394 169  GRIN2B 
16:3658493-3730187 179 179 CREBBP 
7:65063329-65358874 185  TPST1 
18:59108376-59130340 195  BCL2 
17:376995-590176 200 200 VPS53 
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1:108071476-108071476 209  VAV3 
22:30685455-30847431 217 217 SLC5A1 
12:52902996-53179294 223  CBX5 
12:52902996-53179294 223  HNRNPA1 
12:52902996-53179294 223  ITGA5 
17:54984029-55131379 232  CLTC 
17:5361052-5446498 235 235 NLRP1 
6:109105980-109118020 237 237 FOXO3 
3:39279468-39475164 240  CCR8 
3:39279468-39475164 240  CX3CR1 
7:140919185-141111832 245 245 SSBP1 
1:168915903-169011513 257  PRRX1 
16:14536989-15493575 259 259 PLA2G10 
16:31750349-45189424 289 289 SHCBP1 
19:10661268-10692673 294 294 DNM2 
19:10661268-10692673 294 294 ILF3 
19:43465362-43591388 296 296 PSMD8 
14:30154839-30181611 297 297 SCFD1 
4:24370289-24438525 306 306 SOD3 
12:29724596-29734362 315  TMTC1 
1:216401895-216622920 317 317 TGFB2 
15:63630207-63901909 334 334 SLC24A1 
6:154316536-154504746 352 352 OPRM1 
13:107712281-107754318 366 366 TNFSF13B 
7:93894152-94208343 372 372 COL1A2 
17:64029901-64172781 375 375 PRKAR1A 
7:6702059-6709622 392 392 ZNF12 
5:7850291-7885119 400 400 ADCY2 
12:116028796-116173554 405 405 FBXO21 
12:116028796-116173554 405 405 NOS1 
11:110974172-111139465 416 416 PPP2R1B 
20:57019769-57031040 446  TUBB1 
1:10997169-11216546 450 450 EXOSC10 
1:10997169-11216546 450 450 FRAP1 
1:10997169-11216546 450 450 TARDBP 
2:119447658-119459054 451 451 MARCO 
9:133447401-133460974 459 459 RAPGEF1 
18:72239551-72323185 467 467 ZNF516 
10:6175031-6201787 479  RBM17 
4:111015411-111093375 498 498 EGF 
8:142030361-142093418 504 504 PTK2 
2:182107731-182166048 547  ITGA4 
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9:122537416-122650109 551 551 PSMD5 
9:119463408-119557665 556 556 TLR4 
3:197235139-197311602 569 569 TFRC 
1:22281114-22281114 575 575 CDC42 
1:159311752-159447136 577 577 B4GALT3 
5:179870080-179884180 580 580 CCR4 
8:56517026-56520828 586 586 XKR4 
13:40525677-40616108 589 589 WBP4 
12:15652110-15671192 603  EPS8 
6:152328988-152334353 606  ESR1 
2:178496734-178541360 613 613 PDE11A 
8:134331714-134332521 623 623 NDRG1 
6:41881300-42042625 646 646 CCND3 
6:41881300-42042625 646 646 MED20 
3:170577457-170694461 667 667 EVI1 
3:170577457-170694461 668 668 EVI1 
5:179201385-179206426 691 691 LOC51149 
22:38044162-38044162 718 718 RPL3 
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